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ABSTRACT
Aims and background: The purpose of this study was to investigate movement 
disturbances in schizophrenia and Restless Legs Syndrome (RLS). Schizophrenia 
is associated with impaired cognitive, attentional and perceptive symptoms, but 
also with motor control abnormalities, such as akathisia. Akathisia resembles 
cardinal symptoms of RLS, like restlessness in legs. Motor and postural controls 
are supported by central regulation of dopamine transmission. Dysregulation of 
dopamine is considered to be one of the background factors in schizophrenia 
and RLS. Antidopaminergic agents alleviate symptoms in schizophrenia, whereas 
dopaminergic agents are effective in RLS. 
Methods: Transcranial magnetic stimulation (TMS) allows investigation of the 
functions of central motor pathways and inhibition in the central nervous system 
(CNS). After a single pulse TMS on the dominant and non-dominant motor 
cortex areas motor evoked potentials (MEP), motor conduction time (MCT), 
central conduction time (CMCT) and central silent periods (CSP) were elicited in 
the respective Abductor digiti minimi (ADM) and Tibialis anterior (TA) muscles. 
Intramuscular electrodes were applied as a precise recording technique. 
Computerized force platform posturography (CFPP) allows investigation of the 
sensorimotor neural and attentional mechanisms in the CNS needed to maintain 
postural stability. Center point of pressure forces (CPPF) and the center point of 
force velocity (CPFV) were measured during the subject`s stance eyes open and eyes 
closed on a stable computerized platform. Identical TMS and CFPP study procedures 
were performed in volunteers with schizophrenia on long-term antipsychotic 
medication and in volunteers with RLS in comparison to healthy controls. The 
CFPP was repeated in subjects with RLS after a single day intervention with a 
dopaminergic agent. 
Findings: Consistent with earlier TMS research, no signi cant differences or 
side-to-side differences in the function of corticospinal motor pathways between or 
within the study groups were observed. Interestingly, in our study central inhibition 
was found to be disrupted into multiple separate CSPs. The number of CSPs was 
signi cantly higher in the dominant ADM in subjects with schizophrenia and in 
subjects with RLS compared to the controls. Atypical antipsychotics tended to 
prolong, while conventional antipsychotics tended to shorten CSP in schizophrenia. 
The CFPP studies demonstrated that in schizophrenia, closing the eyes had less 
impact on the CPFV than in controls. Contrary to that  nding, subjects with RLS 
demonstrated lower sway velocity eyes open compared to controls. Pramipexole 
intervention balanced the CPFV differences. 
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ABSTRACT
Conclusions: Motor inhibitory control was changed in RLS and schizophrenia, 
appearing as repeated suppression of muscle activity preferably in the dominant 
ADM. The ability of controlling the upright stance was not impaired per se in 
schizophrenia or in RLS. However, it was discovered a defect of visual compensation 
in schizophrenia, and in turn, a hyper compensatory effect of vision on postural 
control in RLS. Schizophrenia and RLS may share the subcortical CNS origin involved 
in the pathophysiology of the motor control and related dopamine dysregulation. 
Conversely, the observed different interaction patterns in handling the visual 
component during the postural stance refer to different feedback mechanisms in 
concern of motor and postural control in schizophrenia compared to RLS.
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1. INTRODUCTION
Most medical disorders consist of a continuum with two extreme endings, where 
most cases can be located somewhere in the middle of the continuum. Minor mental 
or neurological signs often precede major clinical somatic, neurological or psychiatric 
symptoms. Even though schizophrenia is included in psychiatric disorders, persons 
with schizophrenia also exhibit minor neurological signs indicating slight cerebral 
dysfunction, particularly regarding the motor coordination, sensory integration, 
developmental re exes and patterns of lateralization. These “soft neurological 
signs” often precede the outbreak of illness and may be present in  rst-episode 
schizophrenia (Dazzan et al., 2002). 
Restless Legs Syndrome (RLS) is considered to be a neurological and a 
sensorimotor disorder, mainly manifesting as forced movements and indescribable 
sensations in the legs. RLS is also classi ed as a sleep disorder due to sleep interfering 
symptoms. RLS is often followed by clinical manifestations of anxiety, depression 
and unspeci c inner discomfort. The burden of the somatic symptoms can be 
considerable but they cannot explain all “soft mental signs” experienced by persons 
with RLS (Phillips et al., 2000, Hornyak, 2010).  
Applicable investigation tools, transcranial magnetic stimulation and 
computerized force platform, made the primary purpose of this study possible: 
the closer inspection of the central motor control in these two distinct, but similar 
kinds of movement disturbances exhibiting disorders. The secondary purpose was 
to diminish the gap between psychiatry and neurophysiology. 
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2.1. Schizophrenia
“Outspread  ngers often show  ne tremor... The expression of the face, 
vacant, immobile, like a mask, astonished, is sometimes reminiscent of 
the rigid smile of the Aeginetans... Simple movements are stiff, slow, 
forced.” (Emil Kraepelin, 1919)
Since the days of Kraepelin and Bleuler it has been known that minor signs of 
motor abnormalities emerge in a signi cant proportion of persons suffering from 
schizophrenia. An early sign of incipient schizophrenia can be a loss of the natural 
gracefulness of body movements. It is estimated that 10 to 25 percent of persons 
with schizophrenia have such visible abnormal body movements unrelated to 
antipsychotic drug treatment. Neuroleptic agents may cause similar phenomena 
(Grebb and Cancro, 1989).
 It is well known that many persons with schizophrenia do not differ from healthy 
people or persons with other psychiatric disorders in appearance, but sometimes 
persons with schizophrenia can be  recognized without seeing the person’s face, but 
by paying attention to the gait or  gure of the subject’s walk. The impression is based 
on a slight abnormality of motor activity typical for schizophrenia. The expression 
“Praecox Gefühl” was created by a Dutch psychiatrist, Rümke who claimed that the 
diagnosis of schizophrenia was sometimes made more or less through intuition. 
The term “praecox feeling” precedes the neuroleptic era. It is an outdated term, 
but important when efforts are made to understand and describe the clinical core 
of schizophrenia (Parnas et al., 2011). 
Impairment of motor development and  ne motor coordination can predict 
schizophrenia spectrum disorders in adulthood and may relate to a genetically 
determined higher risk to develop schizophrenia (Crow et al., 1995). Neurological soft 
signs are minor “soft” neurological abnormalities in sensory and motor performance 
that can be detected during clinical examination. Neurological soft signs can be 
categorized as de cits in 1) integrative sensory function (possible origin in the 
parietal lobe dysfunction), 2) de cits in motor coordination identi ed by testing 
general co-ordination, intention tremor,  nger-thumb opposition, balance and gait 
and 3) de cits in performing complex motor task (possible origin in frontal-basal 
ganglia circuitry). Vestibular responses of schizophrenic patients have been studied, 
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but without consistent results (Levy et al., 1978). Abnormalities have been reported 
in eye movements, pursuit and saccadic movements and developmental re exes 
(Stevens et al., 1982, Grif ths et al., 1998, Boks et al., 2000). Abnormal rapid eye 
movements, saccades, during attempts to follow a moving subject smoothly are seen 
in approximately 50 to 80 percent of individuals with schizophrenia, in 40 percent 
of their  rst-degree relatives and eight percent of non-mentally ill persons, which 
makes these movement abnormalities perhaps the most important physiological 
marker of schizophrenia. It has been hypothesized that the site of pathology may 
be the frontal lobe input to the basal ganglia and superior colliculus (Grebb and 
Cancro 1989, Buchsbaum, 1990). Smooth pursuit velocity gain seems to be impaired 
early in the course of schizophrenia and may be worsened by long-term (years) 
treatment with antipsychotics. Other indices of smooth pursuit, catch-up saccades 
and ability to predict target movement are adversely in uenced by illness chronicity 
rather than medication (Hutton et al., 2001).
Several studies have demonstrated a lateralized impairment of attention in 
schizophrenia. The most essential  nding is a subclinical right hemineglect which has 
been demonstrated in several studies with blindfolded patients (Harvey et al., 1993), 
however, a major confounding factor is the possibility that neuroleptic medication 
may reverse either normal or deviant asymmetry (Early et al., 1989). A lateralized 
reaction time abnormality with a longer reaction time to targets in the right visual 
 eld as opposed to the left visual  eld was observed among drug-free but not 
among drug-treated schizophrenics (Wigal et al., 1997). Furthermore, lateralization 
may be affected either by eye closure, state of vigilance or both (Lauerma et al., 
1994). Lateralized sensorimotor deviances associated with schizotypal features and 
levodopa have been replicated in some studies (Mohr et al., 2005). 
The mechanical structure of the human skeleton is unstable. To maintain balance, 
continuous postural corrections must be made with muscle activity. Corrections 
are based on the information from several sensory systems and require motor 
coordination. Abnormalities in the postural control system such as degradation 
or defectiveness of a sensory system or reduced capability to make decisions, have 
unstabilizing effects on posture. Reduction of motor coordination has similar effects 
given that the optimal timing, strength or duration of muscle correction is lost, 
greater correction is needed to maintain postural stability (Koles and Castelain, 
1980).
According to traditional psychiatric conception, schizophrenic symptoms mainly 
consist of changes and disturbances in perception, thinking and mood, which 
promote to secondary changes in social behaviour and relationships. Although most 
patients suffer from serious motor disturbances, the symptoms have frequently 
been contributed to side effects of psychiatric medications affecting the motor 
control mechanisms in the extrapyramidal system of the brain. However, some 
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clinical studies demonstrate the opposite and additionally neuroprotective effect of 
antipsychotics have been discussed (Grif ths et al., 1998, Madsen et al., 1999). It 
has been reported that about 36–53% of non-medicated persons with schizophrenia 
have motor symptoms (Owens et al., 1982, Woerner et al., 1992, Caligiuri et al., 1993). 
Schizophrenia related abnormal motor function, disturbances in coordination, 
involuntary movements and impaired  ne motor skills are not completely related 
to antipsychotic medication. Motor disturbances or dyskinesias consist of varying 
degrees of rigidity, bradykinesia, tremor, akathisia and catatonic signs, detected in 
approximately 80% of schizophrenic patients (Yager, 2000).
Neuroleptic induced akathisia (NIA), a side effect of dopamine antagonists, is 
clinically one of the most relevant movement disturbances to be compared to the 
symptoms of RLS (Walters et al., 1991). Individuals suffering from NIA can sense 
subjective muscular discomfort that makes one feel agitated, impatient and restless. 
In most serious stages of NIA one may alternately sit and stand in rapid tact, move 
constantly one´s legs or go around without being able to stand or sit still. These 
symptoms are primary motor and involuntary. Their underlying mechanism is not 
completely understood, but imbalance between noradrenergic and dopaminergic 
system is discussed (Kaplan & Saddock, 1998). 
Various brain structure related abnormal  ndings, such as reduced number 
of GABA-interneurons and reduced gene-expression for GABA-synthesis in the 
prefrontal cortex (Benes et al., 1991, 1999, Akbarian et al., 1995), elevated striatal and 
changed caudal dopamine synthesis and release (Hirvonen et al., 2008, Fusar-Poli 
et al., 2013) favour the concept that schizophrenia is not “just a mental disease”, but 
rather a brain disease, whereby mental and motor symptoms are signs of complex 
interneuronal conduction disturbances and dysregulation of neurotransmitters 
in the central nervous system (Hirvonen et al., 2005, Marsman et al., 2013). 
Current drug treatments, which primarily act at D (2/3) receptors, fail to target 
all currently known schizophrenia related abnormalities. For these reasons, future 
drug development should focus on the control of presynaptic dopamine synthesis 
and release capacity (Howes et al., 2012). 
2.2. Restless Legs Syndrome 
Idiopathic Restless Legs Syndrome (RLS) is a common sensorimotor and sleep-
related disorder and a growing  eld of clinical research interest. The International 
Restless Syndrome Study Group has proposed four minimal clinical diagnostic 
criteria (Walters et al., 1995), later revised (Allen et al., 2003). They include: 1) 
An urge to move the legs accompanied by or because of experienced unpleasant 
sensations in the legs or sometimes in the arms. 2) The symptoms get typically worse 
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at rest or during inactivity. 3) In order to partially or totally relieve the symptoms 
one has to move the legs, body or arms including but not limited to stretching or 
walking until the unpleasant sensations cease. 4) The symptoms get worse at night 
rather than daytime or only occur in the evening or at night. 
Clinicians may misdiagnose or dismiss this treatable and sometimes serious 
disorder or associate it  anxiety or depression related. Sometimes there are depressive 
manifestations. Patients may seek the doctor due to inability to sleep. The prevalence 
of idiopathic RLS has been estimated to be around 1–15% in general population 
(Chokroverty et al., 1999, Allen et al., 2003).  Nonetheless, the prevalence is thought 
to be approximately 2–8% higher, when factoring in the severity and frequency of 
the symptoms (Ohayon et al., 2012). 
RLS shares many features with neuroleptic-induced akathisia (NIA) although 
there is no evidence supporting association between antipsychotics -induced restless 
legs symptoms and polymorphisms of dopamine (D1, D2, D3 and D4) receptor 
genes in schizophrenia (Kang et al., 2008). In a polysomnographic study sleep 
disturbances were milder in NIA than idiopathic RLS. The latter was characterized 
by more violent leg movements (Becker, 1993). A positive response to dopaminergic 
therapy is a common feature of RLS (Montplaisir et al., 1999, Tuisku et al., 2002, 
Schapira et al., 2006, IV). About 80% of RLS sufferers have periodic leg movements 
during sleep, which can interrupt sleep and result in daytime drowsiness. Five 
major diagnostic features of augmentation are identi ed for RLS patients: usual 
time of RLS symptom onset each day, number of body parts with RLS symptoms, 
latency to symptoms at rest, severity of the symptoms as they occur and effects of 
dopaminergic medication on symptoms (Garcia-Borreguero et al., 2007, IRLSSG). 
RLS can occur as a primary disorder or as a secondary condition. Two subtypes 
of RLS have been identi ed based on age at onset of symptoms. Individuals, who 
experience symptoms of RLS before age of 45 years, are more likely to have a family 
history of RLS and a possible genetic predisposition. The progression of this subtype 
disorder is slower, compared to those RLS patients with later onset of symptoms. 
The secondary RLS phenotype is mostly linked to iron de ciency, pregnancy or end-
stage renal disease (Schapira et al., 2006, Allen et al., 2007). Antidepressants such 
as miancerin and mirtazapine (5-HT2 blockade) may provide protection against 
acute akathisia but stimulate restless legs symptoms (Markkula et al., 1997, 1998).
The pathophysiology of RLS is still unknown, but dopaminergic de ciency 
and genetic causes have been proposed. Lack of movement-related potentials in 
myoclonus during the daytime in RLS was considered to be compatible with an 
involuntary mechanism of induction and points towards a subcortical or spinal 
origin of RLS (Trenkwalder et al., 1993). Opioids may also provide a marked relief 
on symptoms of RLS. A question of placebo responds of medication has been raised 
regarding RLS and pharmacotherapy in general (Fulda et al., 2008). In functional 
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and magnetic resonance imaging studies morphologic changes have been found 
in the somatosensory cortex, motor cortex and thalamic gray matter and low iron 
concentration in substantia nigra, especially in the early-onset RLS (Wetter et al., 
2004, Earley et al., 2006).  Changes in the brain iron metabolism are probably 
connected to changes in central regulation of dopamine transmission (Allen et al., 
2007). 
Dopaminergic hypoactivity, increased availability of D(2)–receptors, involvement 
of D(3)- receptors and dysregulation of spinal dopamine  are also strongly suggested 
(Cervenka et al., 2006, Clemens et al., 2006). A gait analysis study revealed 
subclinical abnormal electromyographic activation of the gastrocnemius muscles 
in subjects with RLS, referring to impaired dopaminergic control of supraspinal, 
but also spinal structures in the CNS, affecting the spinal control of gait (Paci et 
al., 2009). 
In familial cases a gene at chromosomal location 9p-24-22 is linked to RLS and 
the expressed mutation is dopamine receptor speci c individual sensitivity (DRSIS). 
The symptoms are triggered during changes in alertness, at sleep hours, resulting 
in insuf cient dopamine transmission. The sensated sensorimotor experiences are 
characterized as typical urge to move the limbs with or without paresthesias. This 
phenomenon leads to motor signs such as periodic limb movements and motor 
restlessness and can temporary be presented as loss of extensor motor system 
dominance over the  exor motor system of the upright position. In Uner Tan 
syndrome, the nonsense mutation in the same gene leads to underdevelopment of 
the neural substrates of upright posture. The defects inclusive dopamine receptor 
de ciency result clinically in severe cognitive dysfunctions, complete loss of extensor 
dominance in extremities, abrupt speech, cerebellar symptoms, and strabismus. 
Both RLS and Uner tan Syndrome seem to be linked to different mutations in the 
same dopaminergic receptor gene, that affects the diencephalons dopaminergic 
system and the neural networks involved in upright position (Akpinar et al., 2009).
Despite the wide-spread interest of research towards RLS, the pathophysiology 
is still unclear and no speci c lesions have been identi ed for RLS. Low iron 
concentration in the central nervous system together with the factors described in 
hypodopamine theory are considered to be crucial etiological issues involved in the 
pathophysiology of RLS (Allen et al., 2007, Miyamoto et al., 2009). 
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2.3. Medication aspects 
2.3.1. NEUROTRANSMITTERS OF CLINICAL RELEVANCE IN SCHIZOPHRENIA 
AND RLS
Some neurotransmitters have excitatory effects, while others have inhibitory effects. 
However, it is the receptor type that modi es the  nal effect of the neurotransmitter. 
Acetylcholine (Ach) is released at all neuromuscular junctions involving skeletal 
muscle  bers, at many synapses in the CNS, at all neuron to neuron synapses in 
the peripheral nerve system (PNS) and at all neuromuscular and neuroglandular 
junctions within the parasympathetic division of CNS. 
Norepinephrine (NE) is widely distributed in the brain and in the parts of CNS. 
It has typically an excitatory effect. Dopamine is released in many areas of the brain 
and has either excitatory or inhibitory effects, which play an important role in precise 
control of movements. If the neurons that produce dopamine are damaged, it may 
result a Parkinsonism like state, with stiffness and rigidity of the muscles. Serotonin 
is an important CNS neurotransmitter for attention and emotional regulation, even 
for mood regulation. Gamma-aminobutyric acid (GABA) has generally an inhibitory 
effect, but its function is not completely understood. In the CNS GABA appears 
to reduce anxiety (Martini, 2007). Dysregulation of dopamine interactions and 
interactions between GABAergic and dopaminergic neurotransmitter systems may 
play an important role in producing diverse symptoms of schizophrenia (Stahl, 
2010).
2.3.2. ANTIPSYCHOTIC MEDICATION: CONVENTIONAL NEUROLEPTICS AND 
ATYPICAL NEUROLEPTICS 
There are four main dopamine pathways relevant to antipsychotics pharmacology. 
The mesolimbic to cortical tract projection (mesolimbic and mesocortical pathways) 
is hypothesized to be responsible for the antipsychotic effects and the substantia 
nigra to striatum projection (nigrostriatal pathway) for the Parkinsonisms side 
effects. Tuberoinfundibular pathway transmits dopamine from the hypothalamus 
to the pituitary gland. Dopamine release in the tuberoinfundibular pathway inhibits 
prolactin release (Stahl, 2010). 
Antipsychotics can be divided into two main categories: conventional 
antipsychotics and atypical antipsychotics. The potency of dopamine receptor 
antagonists (for example chlorpromazine, haloperidol, sulpiride) correlates with 
their af nity with dopamine 2 receptors. They prevent endogenous dopamine from 
activating the receptors.
Atypical antipsychotics of clozapine-type are effective especially through 
serotonin-dopamine antagonism. Clozapine is chemically related to serotonin-
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dopamine antagonists, olanzapine and quetiapine. Clozapine has a high potency 
of binding dopamine type 1, type 3, type 4 and serotonin type 2 (5HT-2) and 
noradrenergic alpha (1) receptors. It also has antagonist activity at muscarinic 
and histamine type (1) receptors. Clozapine is indicated in treatment –resistant 
schizophrenia and in prevention of tardive dyskinesias. Zotepine has a chemical 
structure similar to clozapine. Zotepine acts by blocking both dopamine 1 and 2 
receptors and blocks four serotonin subtype receptors and histamine H 1 –receptor. 
It is a potent inhibitor of noradrenaline reuptake (Fleischhacker et al., 1997, Stahl, 
2010).
2.3.3. PHARMACOTHERAPY OF RLS 
Symptoms of RLS have been treated by dopaminergic agents, benzodiazepines, 
anticonvulsants and opiates, but dopamine agonists are considered  rst-line therapy 
(Kushida et al., 2006, Trenkwalder et al., 2009). For primary RLS ropinirole and 
pergolide may be the most effective dopamine agonists to relieve paraesthesia 
and motor restlessness. Gabergoline and levodopa are also effective, as well as 
antiepileptic drugs like gabapentin (Vignatelli et al., 2006). Also other dopamine 
agonists like pramipexole is considered to be effective. Pramipexole is well tolerated 
and has a high selectivity for DA 2 and DA 3 -receptors. A single oral dose of 0.125-
0.750 mg alleviates in most cases sensorimotor RLS symptoms in the legs (Tuisku 
et al., 2002, Montplaisir et al., 2006, McCormack et al., 2007, Trenkwalder et al., 
2007, Garcia-Borreguero et al., 2012).
However, many people with restless legs syndrome  nd that medications that 
work initially become less effective over time. Clinicians and persons with RLS 
have recognized that there is no single medication that works for every person 
with RLS and that a drug that relieves one person’s restless legs may actually make 
symptoms in another person worse. All these facts, inclusing the broad spectrum of 
pharmacological agents used to alleviate RLS symptoms, are confounding factors. 
A placebo effect and a possibility of psychogenic features cannot be ruled out.   
2.4. The human motor control system and its integration to the 
central nervous system
2.4.1. MOTOR CONTROL 
The CNS consists of the brain and spinal cord. The posterior gray horns of the spinal 
cord contain somatic and visceral sensory nuclei. The anterior grey horn nuclei 
contain somatic motor neurons. The white matter in the spinal cord can be divided 
into six columns, each of which contains tracts. Ascending tracts relay information 
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from the spinal cord to the brain and descending tracts carry information from the 
brain to the spinal cord. The peripheral nervous system (PNS) forms the nerve 
tissue that takes care of the rest of the human body. The sensory neurons deliver 
information to the CNS and motor neurons distribute commands to peripheral 
effectors. Interneurons interpret information and coordinate responses.
Re exes are automatic responses to stimuli coming from inside or outside of 
the body. Spinal re exes can be monosynaptic, polysynaptic or intersegmental. 
A monosynaptic re ex, like the stretch re ex, automatically regulates skeletal 
muscle length and muscle tone, involving as sensory receptors muscle spindles. 
The postural re ex maintains one`s normal upright position. Polysynaptic re exes 
can provide more complicated responses than monosynaptic re exes and involve 
pools of interneurons. Their anatomical distribution may contain several segmental 
levels and involve reciprocal inhibition, too.  They also have reverberating circuits, 
which prolong the re exive motor response. When several re exes co-operate, a 
coordinated response can be produced.
The brain can facilitate or inhibit re ex motor patterns based in the spinal cord. 
Spinal re exes produce consistent stereotyped motor patterns that are triggered by 
speci c external stimuli, but they can also as needed be activated by certain brain 
centers. Relatively few descending pathways can control complex motor functions. 
Motor control involves a series of interacting levels, of which the monosynaptic 
re exes form the lowest and highest levels consist of the brain areas that modulate 
and build on re exive motor patterns (Martini, 2006).
2.4.2. VISUAL PROCESSING 
Vision is one of the most important special sense that humans own. The visual 
pathway begins at the photoreceptors and ends at the visual cortex of cerebral 
hemispheres. The perception of a visual image re ects the integration of information 
arriving at the visual cortex of the occipital lobes. Many centers of the brain stem 
receive visual information from the lateral geniculate nuclei or through the collaterals 
from the optic tract. Motor commands issued by superior colliculi of mecencephalon 
control unconscious eye, head or neck movements in response to visual stimuli. 
Visual information will be established also to control and regulate the circadian 
rhythm and daily pattern of visceral functions. Beside the detection of light and 
dark, motion perception is one of the most important capabilities of the visual 
system (Berne and Levy, 2000).
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2.4.3. POSTURAL CONTROL SYSTEM 
Various re exes assist in postural adjustments that occur as the head is moved or the 
neck is bent. These re exes are triggered by the receptors including the vestibular 
apparatus and stretch receptors in the neck. Also the visual system contributes to 
postural control. 
The vestibulocochlear re ex occurs, when the head is turned to one side, so the 
eyes will be automatically rotated to the opposite site and both eyes are directed to 
the same direction through the same angle as head (conjugation). The alternating 
slow and fast eye movements are called nystagmus, which take place when the eyes 
respond to head movements and keep on tracking the object. A similar response 
pattern affects the neck muscles, called vestibulocollic re ex. Simultaneously 
contractions of extensor (antigravity) muscles increase and prevent the body to 
fall to the stimulus side. The neural mechanisms behind these re exes lie in the 
semicircular ducts and the stimulation of their receptors. 
Other postural re exes depending on the vestibular apparatus tend to keep the 
body position normal without bending the neck. Tonic neck re exes are triggered, 
if the neck is bent. Then the body position is kept by postural correction opposite 
to those evoked by vestibular stimulation. Righting re exes tend to restore the 
position of head and body in space to normal, involving vestibular apparatus, neck 
stretch receptors and mechanoreceptors in the body wall.
Movements in the eyes are generally conjugate. A rapid conjugate movement 
of the eyes is called a saccade. Once the eyes have targeted a visual object,  xation 
is maintained by smooth pursuit movements. These do not take place in the dark, 
because they require a visual target. Without these microsaccades the retina would 
lose sight of the target and adapt.
Horizontal eye movements are organized by the horizontal gaze center, located 
near the abducens nucleus in the pons. There is also a vertical gaze center in the 
midbrain area. Connections to the motor nuclei are made to inhibit the antagonistic 
muscles of eyes. The frontal eye  elds in the premotor region of the frontal lobe 
trigger voluntary saccadic eye movements. The occipital eye  elds are involved 
in smooth pursuit movements, optokinetic nystagmus and visual  xation and 
in uence the vertical and horizontal gaze centers. A lesion in the posterior parietal 
cortex causes de cit in visual guided movements. Humans may develop a neglect 
syndrome, where one is unable to recognize objects placed in the contralateral hand 
and unable to draw three-dimensioned objects accurately. One can even believe 
that the contralateral limbs even do not belong to him (Berne and Levy, 2000).
Mechanoreceptors are sensitive to stimuli that distort their cell membranes. 
Tactile receptors provide sensations of touch, pressure and vibration. The 
sensitiveness to tactile sensations may be altered by infections, diseases, or by 
damaged sensory neurons or pathways. Proprioceptors monitor the positions of 
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joints (receptors in joint capsules), the tension in tendons and ligaments (Golgi 
tendon organs) and the state of muscle contraction (muscle spindles).
The cerebellum coordinates rapid, automatic adjustments that maintain balance 
and equilibrium. The corrections in muscle tone and position are made by modifying 
the activities of motor centers in the brain stem. The cerebellum registers and 
compares the motor commands with proprioceptive information performs the 
needed adjustments to make the movement smooth. (Martini, 2006)
2.5. Transcranial magnetic stimulation
2.5.1. INTRODUCTION
The examination of the descending motor pathways from motor cortex has become 
more easily available after the introduction of transcranial magnetic stimulation 
(TMS) (Barker et al., 1985). The device for TMS, the magnetic stimulator, consists 
of a high voltage capacitor and a coil. The capacitor is charged to a high voltage 
state, which it is rapidly discharged through the coil. The respective current  owing 
through the coil generates the desired magnetic  eld. A time-varying  ux density 
of the magnetic  eld induces an electrical  eld in any conductive volume through 
which it passes. Neural tissue, such as cortex of the brain is easily elicitable by TMS. 
Activation of motor cortex can be measured as different types of motor responses 
in the desired muscles (Barker et al., 1985, 1986, 1991). 
Motor cortical excitability can be explored by several measures with the help 
of TMS, like axon excitability and inhibitory and excitatory synaptic excitability. 
Cortical inhibition can be measured as short-interval intracortical inhibition (SICI), 
cortical silent period (CSP) and long-interval intracortical inhibition (LICI) and 
short latency afferent inhibition (SAI). TMS or repeated TMS themselves can also 
cause modulation on neurotransmitters or neuromodulators. TMS measures can be 
used to study drug-effects at the system levels of cerebral cortex. The following cited 
acute drug effects on the TMS measures can differ from the chronic drug effects. 
2.5.2. TMS PARAMETERS: MOTOR CONDUCTION AND MOTOR THRESHOLD
The threshold for inducing motor evoked potentials is called motor threshold (MT). 
Motor threshold is a basic measure of excitability within the corticospinal system, 
showing rather stable values, but minor hemispheric differences within individuals 
(Cicinelli et al., 1997). It is de ned as the minimum intensity that is necessary to 
elicit a small motor evoked potential (MEP) at rest (RMT; resting motor threshold) 
or during a muscle contraction (AMT; active motor threshold) in the target muscle 
27
in at least half of the trials. A decrease in MT refers to increased neuronal excitability 
and the increase of MT indicates decreased neuronal excitability. Motor threshold is 
lower in the voluntarily contracting muscle than in the resting muscle. Acute intake of 
drugs relevant in this study and having a main mode of action with neurotransmitters 
GABA (A,B), dopamine (DA agonists, antagonist), norepinehrine (NE), serotonin 
or acetylcholine (Ach) do not signi cantly affect the motor threshold. (Di Lazzaro 
et al., 2000, Ziemann et al., 2004). 
Motor evoked potential amplitude is a measure of distribution of the excitability in 
the corticospinal system. Amplitude increases with stimulus intensity in a sigmoidal 
fashion. The MEP size re ects the number of activated motor neurons by a TMS 
pulse. A MEP amplitude may be affected by neurotransmitters glutamate GABA 
and modulators of neurotransmission like DA, NE, 5-HT and Ach.  Drugs relevant 
to this study, like lorazepam (modulating GABA A) and cabergoline (dopamine 
agonist) may reduce the MEP amplitude, whereas haloperidol (DA antagonist) 
may increase it.
Motor conduction time (MCT), sometimes described as MEP latency, is the time 
taken between activation of pyramidal neurons in the cortex by a TMS pulse and 
time taken for contraction of the target muscle (Ziemann et al., 2004, Edwards et 
al., 2008). Central motor conduction time (CMCT) can be calculated by subtracting 
from the MCT the time taken from the stimulation of the exit zone in the spinal 
root to the beginning of the contraction in the peripheral target muscle (Edwards 
et al., 2008). 
2.5.3. TMS MEASURES OF INHIBITION: CENTRAL SILENT PERIOD 
Central silent period (CSP) re ects the interruption of voluntary activity in the 
electromyography (EMG) of the target muscle induced by TMS. CSP duration 
increases almost linearly with stimulus intensity and may raise to 200–300ms in 
hand muscles. The early part of CSP is assumed to originate in the spinal cord and 
the later part in supraspinal structures, probably in the motor cortex (Inghilleri et 
al., 1993, Ziemann et al., 1996). The whole CSP is claimed to be of cortical origin 
and generated in the primary motor cortex (Roick et al., 1993, Schnitzler et al., 
1994). CSPs are well repeatable within individual measurements and occurrence is 
normally symmetric (Roick et al., 1993). The CSP is probably controlled by complex 
extrapyramidal systems having numerous interneuronal synapses associated with 
(GABA-B ergic) inhibitory circuits onto the pyramidal cells (Capaday et al., 2000, 
Siebner et al., 2000, Trompetto et al., 2001, Edwards et al., 2008). Drugs relevant 
to this study, like lorazepam, L-DOPA (dopamine precursor) and DA agonists may 
lengthen CSP (Priori et al., 1994, Zieman et al., 2004). 
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2.5.4. OTHER TMS METHODS FOR MEASURING INHIBITION: MEASURES OF 
PAIRED PULSES TMS
This method will be elicited by stimulating the motor cortex by two successive TMS 
pulses:  rst a conditioning pulse followed by a test pulse, which has to be delivered 
within a short interstimulus interval through the same stimulator coil. If the motor 
response to the test pulse is decreased, this re ects inhibition, if it is increased this 
indicates facilitation, however depending on the time interval between the stimuli.
SICI can be measured by using a preconditioning (sub-threshold) pulse followed 
after a short interstimulus interval (2–5 ms) by a supra-threshold second pulse. 
It is assumed that the  rst pulse produces an inhibitory post-synaptic potential at 
the corticospinal neurones, through activation of a low-threshold cortical inhibitory 
circuit. This inhibits generation of action potential by excitatory post-synaptic 
potentials (EPSPs) elicited by the supra-threshold second pulse. Benzodiazepines, 
like lorazepam and diazepam, GABA-A agonists and DA agonists seem to enhance 
SICI (Inghillieri et al., 1996, Daskalakis et al., 2003, Ziemann et al., 2004). 
Intracortical facilitation (ICF) is tested in the same way as SICI, but by 
using longer inter-stimulus intervals of 7–20 ms. In short-interval intracortical 
facilitation tests follow also the same protocol, but the  rst pulse is supra-threshold 
and the second subthreshold or both pulses are about the threshold intensity. 
Benzodiazepines, other GABA A and DA agonists seem to reduce ICF, whereas DA 
antagonists (haloperidol, olanzapine) increase it (Inghillieri et al., 1996, Daskalakis 
et al., 2003, Ziemann et al., 2004)
Duration and magnitude of LICI that seems to re ect a long-lasting inhibition 
depend on the intensity of supra-threshold pulses. LICI differs from SICI, but it is 
moreover similar to CSP. LICI is assumed to be mediated via GABA-B receptors. 
Benzodiazepines and GABA A agonists seem to reduce LICI (Inghillieri et al., 1996, 
Ziemann et al., 2004).
SAI is de ned to be an inhibition or reduction of MEP. SAI is produced by 
applying a conditioning afferent pulse to the median nerve at the wrist about 20 
ms prior to TMS of the contralateral motor cortex, relevant to hand muscles. SAI is 
reduced by Ach-antagonist (scopolamine) and thus distinct from SICI (Di Lazzaro 
et al., 2000).
2.5.5. TRANSCALLOSAL INHIBITION 
Transcallosal inhibition can be measured as transcallosal conduction time, meaning 
the conduction time from ipsilateral to contralateral motor cortex through the 
corpus callosum. Transcallosal inhibition can be investigated with single pulse and 
paired pulse techniques (Ziemann et al., 2004, Berardelli et al., 2008, Edwards 
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et al., 2008). Conventional and typical antipsychotics may have different effects on 
the inhibitory systems. Olanzapine has been observed to enhance the transcallosal 
inhibition and increase the duration correlating with the dose compared to persons 
with schizophrenia on risperidon and to controls (Fitzgerald et al., 2002). 
2.6. Computerized force platform posturography (CFPP) 
Postural stability can be measured with force platform posturographic technique 
that reveals more information on the muscular efforts needed to maintain the 
balance than other traditional methods, like visual observation of the body sway. 
Many diseases may affect the complicated multisensory postural control system. 
If one´s human sensory system fails, another structure will try to compensate it. 
Control reduction of one sensory system will cause changes in postural control 
forces. Postural control is age-dependent. Middle-aged persons manage to control 
their postural stability better than children and elderly subjects. The importance of 
visual information grows with growing age of elderly people (Hytönen et al., 1993). 
Persons with training background, like shooters, can control their postural stability 
better than not trained persons.
The force platform used in our studies was borrowed from Heikki Aalto 
(Master of Science in engineering), who constructed and built the combination 
of a computerized tape-machine and the force platform and based his academic 
dissertation on this methodical aspects and practical applications (Aalto, 1997). The 
model originates to the platform, introduced 1974 by Terekhov (Terekhov, 1974). 
It measures force differences between sides in the vertical direction. Force sensing 
elements are located in each four corner between two rectangular steel plates. The 
analog signal captured by the load cells, was converted to a digital one. 
The standing subject applies his mass and gravity forces on the platform surface 
with his feet. Practically, center of foot pressure or center point of force (CPF) is 
calculated to omit the weight of the subjects from the measured forces at the moment. 
The CPF is an imaginary point, where all the forces applied on the platform are 
thought to concentrate. As direction-dependent parameters can be calculated the 
average position of CPF, the movement of the CPF in forward-backward or right 
–left directions. The length of the trace of the CPF is the most commonly used 
direction-independent parameter. The path length divided by the duration of test 
gives the average CPF velocity (CPFV, m/s). The acceleration of the CPF can also 
be used. The subjects can be exposed to different disturbing stimuli to test the 
neural machinery involved in the postural control, including visual  eld, muscle 
stimulation with local vibration, support surface vibration or low-frequency sound, 
to get further distinguished information of the sensorial conditions.
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The force platform posturography provides an accurate and objective method 
of measuring postural stability with reliable applications in vestibular research and 
in clinical use (Aalto H, 1997). The measurements are easily repeatable, but the 
method is non-speci c meaning that no diagnoses can be based only on the results 
obtained with the help of this method (Di Fabio et al., 1996, Kingma et al., 2011)
2.7. Review of the earlier TMS studies 
2.7.1. SCHIZOPHRENIA 
Over the last two decades the interest in investigating schizophrenia by TMS has 
been wide. The very  rst TMS investigation of motor function in schizophrenia 
(Puri et al., 1996) showed, that in non-medicated schizophrenic patients the MEP 
latency following TMS was signi cantly shorter than in healthy subjects, but no 
signi cant differences were obtained in the mean latency of suppression of EMG 
activity (CSP) or in the stimulus thresholds for MEPs or CSPs between schizophrenia 
and control groups. Behind these original  ndings it was proposed to be a relative 
lack of corticospinal inhibition of motor responses, a direct activation of corticospinal 
neurons or an abnormal function of peripheral nerve or neuromuscular junction 
in schizophrenia. 
Healthy individuals demonstrate differences between dominant and non-
dominant hemispheric sides, seen as shortened silent period in the dominant 
hand. Healthy right-handed people generally show a lower motor threshold in 
their dominant left hemisphere, eventually because of more frequent use of their 
right hand (Priori et al., 1999). In general, handedness is associated with a complex 
asymmetry in cortical motor representation (Kawashima et al., 1997, Cracco et al., 
1999, Solodkin et al., 2001). 
Investigation results concerning brain asymmetry and MT in schizophrenia 
have shown a lot variation. MT has been found lower over left hemisphere in 
medicated individuals with schizophrenia (Abarbanel et al.,1998, Daskalakis et al., 
2002), higher in medicated individuals and lower (for non-dominant compared to 
dominant hemisphere) in unmedicated individuals with schizophrenia (Pascual-
Leone et al., 2002, Fitzgerald et al. 2002b). Deviations from the normal asymmetry 
in human brain and corticospinal excitability may re ect a higher risk of developing 
a schizophrenic disorder or refer to a higher severity of general psychopathological 
symptoms (Tiihonen et al., 1999). 
However, several other TMS studies have not shown signi cant differences in 
the motor threshold, in the amplitude or in the latency of MEPs in non-medicated 
individuals with schizophrenia compared to individuals with schizophrenia on 
conventional /atypical antipsychotics and to healthy controls (Abarnel et al., 1996, 
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Boroojerdi et al., 1999, Davey et al., 1997, Pascual-Leone et al., 2002). Some single 
pulse TMS studies have demonstrated that the CSP duration was indifferent or 
signi cantly shorter in medicated subjects with schizophrenia than in healthy 
controls (Fitzgerald et al., 2002 a, b, Daskalakis et al., 2002). Davey et al., 1997 
found that in subjects with schizophrenia on conventional antipsychotic medication, 
the CSP was divided into an early part with a weak suppression of voluntary EMG 
and a later component with a strong suppression of voluntary EMG, whereas the 
latency of CSP was indifferent. 
In some paired pulse studies the  ndings indicated a disrupted cortical inhibition 
in persons with schizophrenia on conventional antipsychotics and in healthy persons 
after intake of haloperidol (Pascual-Leone et al., 2002, Ziemann et al., 1997). The 
observed delay of the maximum suppression of the muscle contraction was supposed 
to be caused by antipsychotic medication that may disrupt the basal ganglia inputs 
to the inhibitory circuits in the motor cortex. Similar deformed CSPs have also 
been seen in persons with Parkinson`s disease (Ridding et al. 1995). CSPs tend 
to increase with increasing stimulation intensities in persons with schizophrenia 
on antipsychotic medical treatment (Wobrock et al., 2009, Soubasi et al., 2010). 
Most of the transcallosal inhibition studies with single pulse TMS technique 
have suggested a longer silent period duration in schizophrenia than in controls. 
Stimuli seem to be transferred normally from one brain hemisphere to another, but 
contralateral inhibitory mechanisms may be activated by the transcallosal stimuli, 
appearing as lengthening of CSP in the contralateral target muscles in persons with 
schizophrenia (Boroojerdi et al., 1999, Fitzgerald et al. 2002a, Hoppner et al., 2001). 
Paired pulse TMS studies have shown rather varying results concerning 
schizophrenia. Shorter CSP duration and reduced SICI have been observed in drug-
free persons compared to medicated persons and shorter CSP in medicated persons 
compared to healthy controls (Daskalakis et al. 2002). Reduced SICI has come 
out in subjects with  rst-episode schizophrenia with limited history of medication 
(Wobrock et al., 2008) and in medicated subjects with schizophrenia in comparison 
to controls (Pascual-Leone et al., 2002, Fitzgerald et al., 2002b). A group of drug-
naïve subjects with schizophrenia had a signi cantly lower resting motor threshold 
to TMS as compared with healthy controls whereas SICI and ICF failed to show 
signi cant differences between the groups (Eichhammer et al., 2004). In general, 
ICF seemed to show rather inconsistent results in the cited studies. A reduced SICI 
has been linked to increased MT and to high symptom severity of schizophrenia. 
A reduced SICI has also been found in other neuropsychiatric disorders (Wobrock 
et al., 2008, 2009). 
It can be concluded that drug-free persons with schizophrenia seem to show 
reduced CSP, but in medicated persons with schizophrenia the CSP duration and 
SICI show a lot of variation depending on the current type of antipsychotic medical 
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treatment and the applicated stimulation intensity. Results concerning motor 
threshold, motor conduction time, MEP size and ICF are rather consistent. The 
obvious differences in the results between various cited studies may re ect different 
methodologies applied in the studies.
2.7.2. RESTLESS LEGS SYNDROME 
In general, earlier TMS studies have shown that descending corticospinal motor 
pathways function correctly in RLS compared to healthy controls. But there are 
several studies showing inconsistent results concerning central inhibitory control, 
especially central silent period (CSP) and intracortical inhibition (ICI). In one of 
the earliest studies, cortical silent period was found reduced in hand and foot target 
muscles (Entezari-Taher et al., 1999). 
In another study ICI was found decreased in muscles of upper and lower limbs, 
whereas intracortical facilitation (ICF) was decreased in the lower limb muscles 
referring to changes in the corticocortical motor excitability in RLS (Tergau et al., 
1999). Another study demonstrated no signi cant differences in CSP (in ADM, 
TA both sides) in between subjects with RLS and controls, but reduced ICI and 
increased ICF were obtained in both ADM and TA muscles. These changes were 
correlating to the body side affected more by sensory-motor symptoms of RLS, 
involving especially arms (Quattrale et al., 2003). A month´s treatment with a 
dopamine agonist did not affect CSP duration in hand muscles (Abductor Pollicis 
Brevis) but it signi cantly increased CSP in foot (TA) muscles (Kutucku et al., 2006). 
In another study with a same kind of study protocol, the results showed  that 
after single pulse TMS no speci c CSP (pre- and post-treatment) changes were 
obtained, but after paired pulse TMS SICI was signi cantly increased after 4week´s 
medication intervention with pramipexole (Scalise et al., 2006, 2010).  One study 
reported a preliminary shorter CSP duration, resulting within 14 days intervention 
with cabergoline in an increase of CSP duration and ending in 90 days´ treatment 
with a decrease of CSP duration, which, however, was still longer compared to 
controls. The symptom severity of RLS did not correlate with the changes of CSP, 
because the RLS symptoms continued improving even after the CSP duration had 
diminished (Gorsler et al., 2007).  
Some other paired pulse studies have also demonstrated that cortical 
hyperexcitability in RLS can be reversed by dopaminergic agents (cabergoline, 
pramipexole) (Nardone et al., 2006, Rizzo et al., 2010). In addition to SICI, SAI 
was observed to be reduced in drug-free subjects with RLS and to be restored by 
dopaminergic medication. The reduction of SAI was considered to be a possible 
contributer in releasing involuntary movements, like typical sensorimotor symptoms 
of RLS (Rizzo et al., 2010).
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 In one study, in which TMS measurements were performed besides at daytime 
also at night-time, active MT tended to increase in healthy controls, whereas it 
and the CSP tended to decrease in drug-naive RLS subjects, without any other 
signi cant differences in other TMS parameters between the groups. Thus, active 
MT and CSP may show circadian variation in RLS, indicating normal corticospinal 
axonal functioning, but possible loss of subcortical inhibition at night time (Gunduz 
et al., 2012).
Conclusive, earlier TMS studies have not demonstrated signi cant differences 
in MT, MEP latency, MEP amplitude, MCT or CMCT in RLS compared to healthy 
controls, neither signi cant side-to-side differences. CSP  ndings have varied, 
but for the most CSP and ICI have been found reduced in persons with RLS 
compared to controls.  Dopaminergic agents seem to lengthen or normalize the 
observed inhibitory de cits temporarily, however without loss of improvement in 
RLS symptoms. The clinical symptoms of RLS do not seem to correlate with any 
observable changes in CSP. 
2.7.3. MEDICATION EFFECTS OF CLINICAL RELEVANCE IN SCHIZOPHRENIA AND 
IN RLS
Central dopamine dysfunction plays an important role in schizophrenia and RLS. 
Dopamine-blocking agents are effective in schizophrenia, whereas dopaminergic 
agents are the drugs of choice in RLS. Dopaminergic drugs (bromocriptine, pergolide) 
and monoamines (serotonin, noradrenaline) may modulate cortical excitability in 
healthy persons (Nikulin et al., 2003, Kähkonen et al., 2004).  GABAergic agents, 
like lorazepam, do not affect the motor threshold, but obviously increase intracortical 
facilitation. Intravenous given diazepam and lorazepam probably affect differently 
the central inhibition (Di Lazzaro, 2005). Atypical antipsychotics, especially 
clozapine, seem to lengthen central inhibition in persons with schizophrenia, 
probably due to interference with GABA B –interneurons, serotonin (5HTC2) and 
D2 receptors (Daskalakis et al., 2008). 
2.8. Postural control in schizophrenia and in RLS 
There are only few studies about postural stability in schizophrenia. In a gravimeter 
study schizophrenic patients with high SANS (Scale for the Assessment of Negative 
Symptoms of Schizophrenia) scores, presented a larger gravimetric area than the 
normal subjects and the patients with schizo-affective disorder (Nakai et al., 1992). 
In another study subjects with schizophrenia demonstrated more postural sway than 
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did the healthy controls. There were no signi cant correlations between neuroleptic 
medication levels and degrees of postural sway (Marvel et al, 2004). Another study 
compared non-alcoholic and alcoholic subjects with schizophrenia and without 
schizophrenia. The study results revealed gait and balance de cit in subjects with 
schizophrenia especially in visual condition (Sullivan et al., 2004). To our knowledge 
there are no earlier studies concerning postural control in RLS. 
However, there are several studies demonstrating alterations of postural re exes 
in Parkinson´s disease, especially in the advanced stages (Rocchi et al., 2002, 
Frenklach et al., 2009). Dopaminergic treatment (levodopa) relieves the symptoms 
of Parkinsonism like stiffness of the limbs and the body, but seems to increase 
the postural sway, which may be in connection to risk of falling. Early automatic 
postural re exes are only partially corrected by dopaminergic treatment and later 
occurring voluntary postural corrections are not improved at all. 
In neuroleptic induced Parkinsonism, like in other similar set of syndromes, 
postural balance destabilizing re exes are considered normal. Other mechanisms 
than dopaminergic motor control systems are suggested to be involved in the altered 
responses observed in Parkinson`s disease (Bloem et al., 1996, Rocchi et al., 2002). 
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3. THE AIMS OF THE STUDY (I–IV)
SCHIZOPHRENIA RESTLESS LEGS SYNDROME
 CFPP STUDY I   STUDY IV
 TMS STUDY III STUDY II   
3.1. CFPP In schizophrenia (study I)
There are only few earlier studies dealing with postural control in schizophrenia. The 
aim of the study was to examine postural stability in subjects with schizophrenia 
in order to see if persons with chronic schizophrenia on antipsychotic medical 
treatment differ from healthy controls in regard with their sway velocity or direction 
of the sway path. The hypothesis was that persons with schizophrenia would have 
dif culties in maintaining the postural balance based on the motor control and visual 
perception deviations associated with schizophrenia. In addition, antidopaminergic 
medication might worsen the postural control compared to non-medicated healthy 
controls. Visual impact on the postural stability was expected to be important in 
maintaining the upright stance in persons with schizophrenia.
3.2. TMS in RLS and schizophrenia (studies II–III)
The aims of these studies were to characterize motor control of the central nervous 
system in individuals with RLS and with schizophrenia with the help of the TMS. 
The main interests of these studies were to investigate these two different chronic 
disorders with over-lapping clinical manifestations of motor symptoms. Even 
though there is a rich literature on TMS research dealing with motor control, 
especially central inhibitory processes and dopamine regulation in these disorders, 
the pathophysiological backgrounds of these motor symptoms are still unclear. A 
different, but replicable and precise technique was applied in this study: the motor 
cortex was stimulated with the help of single pulse TMS on both brain hemispheres 
and muscle responses were measured by using intramuscular recording electrodes in 
the respective target muscles in both under and upper extremities. It was expected 
to  nd no differences in the function of the corticospinal direct motor pathways in 
between the groups (i.e. schizophrenia, RLS, controls) based on the earlier reports. 
The main interests of these studies were to investigate if the central inhibition 
differed signi cantly between the subjects of schizophrenia (study III) or with RLS 
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(study II) compared to healthy controls. In addition, it was interesting to see if any 
similarities or signi cant differences were observable in the inhibitory responses 
between the disorder groups and if the results depended on the site or side of 
stimulation and re ected the motor symptoms the subjects mostly suffered.  
3.3. CFPP in RLS (study IV)
The aim of this study was to research further motor control by examining postural 
control in individuals with RLS with help of the CFPP. The main interest of this 
study was to see how vision and a dopaminergic agent affect the postural control 
in individuals with RLS, because central dopamine regulation and vision play an 
important integrative role in sustaining postural stability and because dopamine 
has a therapeutic effect on symptoms of RLS. It was expected to see to some 
extent symptom relief, but mainly growth of sway velocity and area after intake 
of a dopamine agonist, based on the earlier investigations showing alterations of 
postural re exes and impairment of postural balance in individuals with Parkinson´s 
disease (Bloem et, 1996, Rocchi et al., 2002, Frenklach et al., 2009). 
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4. SUBJECTS AND METHODS (STUDIES I–IV)
4.1. General aspects regarding subjects (I–IV)
Persons having epilepsy, cardiac pacemaker or any magnetically active particles 
in the cranium or brain were excluded from the TMS studies. Also persons with 
other neurological, serious somatic or mental diseases or with a history of alcohol 
or drug abuse, or serious traumatic injuries of the extremities were also excluded. 
Subjects were asked to refrain from taking any psychoactive, CNS affecting or 
any RLS symptoms relieving medications (tramadol, benzodiazepines, levodopa) 
for one week prior the investigation. Subjects with schizophrenia remained on their 
prescribed medication as prescribed by their psychiatrists.  Subjects’ height and 
weight including sociodemographic data were documented. 
The right-handedness of the subjects was assessed with the help of the Edinburgh 
Handedness inventory. The Edinburgh Handedness Inventory is a measurement 
scale used to assess the dominance of a person’s right or left hand in everyday 
activities. A more reliable way to use the inventory is to let an observer assess the 
person, than allow the person himself report the hand use because of the common 
tendency to over-estimate tasks to the dominant hand (Old eld, 1971). In this study, 
the dominance of the brain parts/limbs was de ned by observing and asking the 
subjects. The footedness was mainly based on inquiring the subjects. A computerized 
tomogram of the brain (CT) and an electroencephalography (EEG) had been 
controlled in most of the subjects with schizophrenia recently if this had been seen 
to be necessary to exclude any neurological or neurophysiological abnormalities of 
the brain behind the psychiatric symptoms. 
4.1.1. SUBJECTS WITH SCHIZOPHRENIA AND CONTROLS (STUDY I)
In total 22 right-handed medicated subjects with schizophrenia (8 females, 14 
males) were recruited and diagnosed according to DSM-IV criteria (8 paranoid 
schizophrenia, 12 undifferentiated types and 2 disorganized types) (Table 1). The 
duration of illness was averaged 16.3 years. The mean dose of anti-psychotic 
medication used by the patients was 652 mg in chlorpromazine equivalents. 14 age
 (+2 years) and gender matching right-handed controls  were  recruited from  the
 hospital  personnel.  Exclusion  criteria  for  all  participants  included  symptoms 
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or diagnosis of other mental diseases or current mental symptoms, neurological 
diseases, orthostatic symptoms, a history of alcohol or drug abuse, or a history of 
serious traumatic head injury or lesions of the extremities that might in uence 
postural control. Each participant was clinically examined for neurological and 
somatic symptoms. 
Prior to the clinical investigations, subjects with schizophrenia were evaluated 
using the psychiatric rating scale PANSS (positive and negative syndrome scale), 
which is a medical scale used for measuring symptom severity of persons with 
schizophrenia. Positive symptoms refer to an excess or distortion of normal functions 
(e.g., hallucinations and delusions) while negative symptoms represent a diminution 
or loss of normal functions. PANSS is a 30-item scale, which includes seven points 
that measure positive symptoms, seven points for negative symptoms, and 16 points 
for general psychopathology (Kay et al., 1987) (Table 1). 
Movement disorders and side-effects of antipsychotic medicines were evaluated 
with the help of the following clinical rating scales: 
1. AIMS (abnormal involuntary movement scale) is a medical rating scale that was 
designed to measure involuntary movements known as tardive dyskinesia (TD), 
often related to chronic schizophrenia (Munetz & Benjamin, 1988).
2. SAS (Simpson -Angus scale of extrapyramidal symptoms) is a medical scale used 
for assessing especially neuroleptic induced Parkinsonism (Simpson & Angus, 1970).
3. BAS (Barnes Akathisia Scale) is a medical rating scale that is used for assessing 
the severity of drug-induced akathisia. It is the most widely used rating scale for 
akathisia including objective and subjective items such as the level of the patient’s 
restlessness (Barnes, 1989).
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Table1. Antipsychotic medications (in 100mg chlorpromazine equivalents, CPZ) and sociodemographic 
data of subjects with schizophrenia in study I are presented in table 1. Legend: No= subject identiﬁ cation 
number, DUI = duration of schizophrenia in years, PANSS= Positive and Negative Syndrome Scale. 
No Subtype ofschizophrenia Gender
Age 
(years)
DUI
(years)
PANSS 
(records)
Antipsychotics 
(100mgCPZ equiv.)
1 paranoid female 60 >30 99 500
2 paranoid female 50 14 64 450
3 undifferentiated female 41 20 72 242
4 undifferentiated female 45 17 81 720
5 disorganized female 31 14 103 900
6 undifferentiated female 54 >30 53 472
7 paranoid female 28 8 75 1120
8 paranoid female 42 10 81 100
9 disorganized male 51 >30 109 1200
10 paranoid male 39 21 96 1180
11 undifferentiated male 47 27 102 700
12 undifferentiated male 57 28 65 120
13 undifferentiated male 53 25 88 272
14 paranoid male 47 20 72 50
15 undifferentiated male 28 9 60 1200
16 undifferentiated male 24 1,5 57 500
17 undifferentiated male 38 8 70 600
18 undifferentiated male 32 7 66 517
19 paranoid male 28 9 123 1000
20 undifferentiated male 34 13 98 1400
21 undifferentiated male 33 9 53 500
22 paranoid male 31 8 85 600
4.1.2. SUBJECTS WITH RLS AND CONTROLS (STUDY II)
A total number of six right-handed volunteers with an ICD -10 diagnosis of RLS 
(3 females and 3 males, between the ages of 44 to 71 years) were selected from 
a university hospital clinical population, among which secondary causes for RLS 
had been excluded by carrying out necessary blood tests and specialist medical 
consultations. RLS symptoms were checked prior to the clinical investigation part 
of this study with the help of the Diagnostic checklist criteria for RLS in subjects 
with RLS: ad modum Gibb and Lees (1986) and essential features according to 
Walters IRLSSG (The international Restless Legs Syndrome Study Group, 1995): 
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A. Desire to move the limbs usually associated with paresthesias or dysesthesias. 
B. Motor restlessness. 
C. Symptoms are worse or exclusively present at rest with at least partial or   
 temporary relief with activity. 
D. Symptoms are worse during the evening or at night.
The recruited participants with RLS had a chronic duration of RLS lasting several 
years. They all reported a positive family anamnesis for RLS. Characteristic was 
the worsening of symptoms by time and sensations with same type of unusual, but 
milder symptoms in the arms as in the legs.  PLMD was excluded on grounds of a 
clinical interview performed by an experienced sleep-researcher. 
In addition, six healthy right-handed volunteers (3 females and 3 males between 
the ages of 22 to 49 years) from the hospital personnel were recruited as a control 
group. Clinical somatic and neurological examinations were conducted in all 
participants to rule out any serious somatic, neurological or sensorimotor diseases. 
A history of substance abuse, mental disease or use of neurotropic or any somatic 
medications by potential participants that may impact study  ndings were excluded 
by conducting a short structured psychiatric interview.
4.1.3. SUBJECTS WITH SCHIZOPHRENIA AND CONTROLS (STUDY III)
A total number of 11 subjects with an ICD -10 diagnosis of schizophrenia (5 females, 
6 males, aged from 21 to 70 years old) were included in this study (Table 2). In 
addition, nine healthy volunteers (5 females, 4 males, aged from 22 to 49 years) 
were included as a control group (Table 2). All subjects with schizophrenia were 
on medication: four subjects had clozapine and six subjects had combinations of 
conventional antipsychotics. One of the subjects had since three years treatment 
with zotepine medication, which is an atypical antipsychotic agent like clozapine. 
Three subjects with schizophrenia had additionally lorazepam as needed. The clinical 
duration of chronic schizophrenia was at least one year. Four subjects were left-
handed, the rest of the subjects were right-handed. 
Prior the clinical investigation part of the study subjects with schizophrenia 
were evaluated with the help of the medical rating scales (PANSS, AIMS and SAS). 
Calgary depression scale (Addington & Addington, 1999) was also used to assess 
the level of depression associated with schizophrenia. It appears sensitive towards 
changes in both relapsed and remitted patients with schizophrenia (Table 2).
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4. SUBJECTS AND METHODS
4.1.4. SUBJECTS WITH RLS AND CONTROLS (STUDY IV) 
A total number of 12 right-handed volunteers with RLS (11 females and 1 male, 
mean age 50.7, range 26–62), were included to this study.  They were recruited 
by advertising in a health magazine.  Inclusion criteria were an age of 18–65 years, 
diagnosis of RLS based on IRLSSG (Walters et al., 1995) criteria together with 
chronic over one year lasting symptoms, frequent at least half night occurring 
symptoms and subjectively distressing and harmful symptoms of RLS and right-
handedness. 12 right-handed controls (11 females, 1 male, mean age 49.4 and range 
38–57) were recruited from the psychiatric hospital personnel and from a prison 
personnel. Exclusion criteria for all subjects were current medication during past two 
weeks, a long-term use of any neurotropic drugs, major somatic illnesses, serious 
traumatic injuries of head or lesions of extremities, orthostatic syndromes, secondary 
subtypes of RLS, any other medical causes of insomnia than RLS, and psychiatric 
disorders diagnosed by the structured clinical interview (SCID-I, clinician version) 
(First et al., 1997). In addition, clinical neurological and somatic investigations were 
performed in all the participants, to exclude any symptoms or diseases that might 
cause dizziness or interfere with postural control. 
The subjective symptom severity of RLS, including the latency of falling in sleep 
was evaluated by asking and recorded on both study protocol days in a self-made 
simple model of visual analogue scale (VAS). VAS was selected to be used due to 
lack of validated rating scales for RLS at the time of study procedure (Chokroverty 
et al., 1999). Figure 1 presents an example of VAS and the obtained scores in a 
subject with RLS (Figure 1).
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Figure 1. An example of VAS (Study IV)
Symptoms of akathisia like restlessness were characterized with the help of 
BAS in subjects with RLS (Tuisku et al., 2005). Blood tests (for renal and hepatic 
function, blood glucose, ferritin B-12 vitamin, blood cell account and plasma level of 
haemoglobin) were controlled prior to the investigations to exclude the secondary 
causes for RLS in participants with RLS. 
4.2. Methods
4.2.1. TMS STUDIES II AND III
The methods and the procedure of the studies II and III were identical. TMS was 
performed in both studies by using a commercially available magnetic stimulator, 
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Cadwell MES-10, supplied with a round coil that has an external diameter of about 
9 cm. The stimulation intensity exceeded constantly the motor threshold level. A 
biphasic stimulation pulse was used with an intensity of 60 to 80% of the maximum 
capacity of the device in each series of stimuli. In each series of stimuli, altogether 
 ve repetitive pulses were given with a time interval of 1 to 5 seconds. For the 
stimulation of muscles in upper extremities, the center of the coil was placed at 
the on the corresponding temporal area, contralateral to the side of recording of 
the responses. The most optimal site of stimulation of the muscles in the lower 
extremities was the central area close to the vertex. Adjustments of coil positions 
were made to achieve the most favorable site of the stimuli of respective muscles. 
Two types of responses, the muscle activation in inactive muscle and inhibition 
of muscle activity in maximum preactivated muscle were measured. The recording 
of the responses was performed with Dantec KeyPoint device. The responses were 
recorded by using a pair of monopolar needle electrodes that were inserted to 
Abductor Digiti Minimi (ADM) and Anterior Tibial (TA) muscles at a distance of 3 cm 
from each other. The cathode was positioned proximal to anode. The intramuscular 
recording with needle electrodes enables the measurement of the high frequency 
components of the muscular activity. To measure the motor distal latency (MDL) 
and the latency of F-responses (F) electrical stimuli (rectangular pulses with duration 
of 0.2 ms and intensities of 10 to 50 mA) were given at ulnar and peroneal nerves 
at wrist and at the  bular head on the lateral side of the knee, respectively.
For the analysis of the muscle activation, the following parameters were recorded 
and calculated: 1) Motor conduction time from cortex to ADM (MCTa) and to TA 
(MCTt). 2) MDL= Respective motor distal latency to the stimulation of ulnar and 
peroneal nerves. 3) Latency of F-response to the ulnar nerve stimulation at the 
wrist (Fu) and to the peroneal nerve stimulation at the  bular head (Fp). MDL 
was excluded from the F latency. 4) Central motor conduction time from the motor 
cortex to the neck: CMCTn = MCTa - (Fu/2 + MDL). 5) Central motor conduction 
time from the motor cortex to the lumbar area: CMCTl = MCTt - (Fp/2+MDL). 
Based on studies with TMS of motor cortex, the MEPs show considerable 
amplitude variation (Hess et al. 1987, Rothwell et al. 1987). We therefore considered 
the assessment of amplitudes as such as probably not suitable for quantitative 
analysis. These commonly used TMS parameters measured in this study are 
presented in a semantic picture of a human body (Figure 2).
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Figure 2. The TMS parameters measured in this study  (II, III) are presented in a semantic picture of a 
human body in ﬁ gure 2. Legend: MCT= Motor conduction time, CMCT= central motor conduction time,
ADM= Abductor digiti minimi muscle, TA= Tibialis anterior muscle
For the analysis of the CSP in each voluntarily maximally preactivated muscle, 
the following parameters were recorded on the contralateral side to a series of 
 ve magnetic stimuli: the latency, the duration and the total number of the silent 
periods of the activated muscle (ADM, TA). Maximum preactivation of the muscle 
was de ned as a full interference pattern of the muscle activity in a time frame of 
500 ms and a sensitivity of 1 mV/div. The presence of the CSP was de ned as a 
simultaneous decrease of amplitude of muscular activity below 0.05 mV/division 
in  ve consecutive measurements. Stimulation intensity was the same used to elicit 
MEPs.
4.2.2. THE METHODS IN CFPP STUDIES I AND IV 
The basic measurements were performed in the same way in studies I and IV. A 
custom made force platform was used to evaluate the postural control of the standing 
subjects (Starck et al., 1993). In computerized force platform posturography, the 
force platform is connected to a computer and this measuring system determines 
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center point of force (CPF) from the forces that the standing subject applies with 
his or her feet to the platform. The system also analyses the movement of the CPF 
during the test. This movement re ects the postural control activity; the used forces 
which maintain the balance, their magnitude, duration and direction. 
One of the most used parameters in computerized force platform posturography 
is the center point pressure which is closely correlated to velocity (CPFV), the length 
of the trace of the CPF divided by the duration of the test. Any increase in the activity 
of postural control forces is re ected in this parameter. The average position of the 
CPF is obtained, as the values of the CPF are averaged over a period. When the length 
of the sway path is averaged for a second, the average position of the CPF re ects 
the position of body’s center of mass on the platform surface. From this variable 
the visible leaning angle of the body can be calculated. In this study the change of 
average position is used to quantify the effect of eye closure. This parameter has 
been calculated separately in lateral and anterior-posterior directions.
The platform was placed in both studies in a peaceful, undecorated investigation 
room, at a distance of one meter from a white wall. The subjects stood with their 
shoes on, arms crossed over the chest, heels distanced about 2 centimeters from 
each other, and feet abducted at 30 degrees angle mimicking apendulum position for 
body sway. The subjects were asked to look at a piece of paper placed at the height 
of their eyes and stand still on the platform. The patient stance was recorded  rst 
during the eyes open condition for 30 seconds, and then 30 seconds eyes closed, 
in between there was a 15 seconds adaptation period. In study I the posturographic 
measurements were performed three times per each subject. Figure 3 presents an 
example of posturographic measurements in a participant with schizophrenia and 
in a control of the study I (Figure 3).
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Figure 3 presents the sway of a subject with schizophrenia (1) and of a healthy control person (2) in study 
I. Lines a show forward-backward leaning tendency (upwards-downwards, respectively) and lines b leaning 
to the right and left (upwards-downwards, respectively). The ﬁ rst 30 seconds were recorded eyes open 
and the last 30 seconds eyes closed. There was an adaptation time of 15 seconds between the recordings. 
4.2.3 THE PROCEDURE OF THE STUDY IV WITH PRAMIPEXOLE INTERVENTION 
The basic measurements with the help of the CFPP were performed as described in 
chapter 4.2.2., but posturographic measurements were performed only once (instead 
of three measurements as in study I) in non-medicated and medicated conditions. 
The measurements in subjects with RLS were at  rst measured without medication. 
After intake of pramipexole the posturographic measurements were repeated within 
three-day intervals in between. Subjects with RLS were administered pramipexole 
after the  rst day measurement and informed to take a dose of 0.88mg t.i.d (8.00 
am, 2.00 pm and 8.00 pm). The measurements were performed at 4 pm-6 pm. 
The severity of the symptoms in subjects with RLS were rated and documented in 
non-medicated and medicated conditions. The posturographic measurements were 
not repeated in controls and they did not undergo intervention with medication.
4.3. Statistical methods 
4.3.1. TMS STUDIES II AND III
To analyse differences in between the subjects with schizophrenia (study III) and 
matching controls and in between subjects with RLS (study II) and matching controls 
the groups (i.e. schizophrenia/RLS and control groups) were compared using the 
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Mann Whitney test. Side-to-side differences within the groups were compared using 
Wilcoxon signed rank test for related samples. Non-parametric tests were applied, 
because of the small sample sizes (n<11), which were not normally distributed. The 
level of signi cance was set p< 0.05. PASW for Windows version 18 was used in 
studies II–III.
In addition, in study III the subjects with schizophrenia were divided into two 
subgroups according to the type of the antipsychotic medical treatment they were 
taking (conventional or clozapine type of antipsychotics). Intercorrelations between 
the clinical parameters and the TMS measures were calculated with the help of the 
Spearman´s correlation test using Bonferroni -correction in between the subgroups. 
In study II the comparison for the several inhibition periods was performed with 
the help of the Chi-square test.
4.3.2. CFPP STUDIES I AND IV
In study I non-parametric tests were used because of the relatively small number 
of subjects (n=22). The results were statistically analyzed using medians of the 
three measurements (mean value), 95% con dence limits of median differences and 
Mann-Whitney two-tailed test. SPSS for Windows was used to analyze the results. 
In study IV the statistical analysis for the sway velocity and CPF shift and the 
changes from conditions eyes open to eyes closed conditions in controls and in non-
treated and treated conditions of participants with RLS were performed with the 
help of non-parametric Mann Whitney -test for independent samples between the 
groups (i.e. RLS non-medicated / medicated and controls). Wilcoxon -test for related 
samples was used to analyse results within the groups (i.e. RLS non-medicated, 
RLS medicated and controls). The Spearman`s test with Bonferroni-correction was 
used to analyze intercorrelations between the Romberg´s quotient and the CPFP 
parameters and clinical parameters, before and after medication intervention in 
subjects with RLS. The level of signi cance was set p<0.05. PASW for Windows 
version 18 was used to analyze the results.
4.4. Ethical considerations
Clinical evaluations and measurements of the subjects with schizophrenia in studies 
I and III as well as the controls in study II were performed at the Laboratory of 
Clinical neurophysiology in Ekåsen Psychiatric Hospital, which belongs to Helsinki 
University Hospital. Respective clinical parts of the study II in subjects with RLS 
were performed in the university and community hospitals in Turku. 
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Clinical evaluations and measurements of the RLS subjects of the study IV were 
performed at the department of psychiatry in Lapinlahti Hospital, belonging to 
Helsinki University Hospital. The evaluations and measurements of the controls 
were performed in Psychiatric Hospital of Vantaa Prison. Informed consent was 
obtained from all the participants and the study was approved by the Ethics 
Committees of Helsinki University Hospital in Helsinki and in Ekenäs attributable 
to ethical standards stipulated in the1965 Declaration of Helsinki. 
There were some ethical aspects to be considered in this study. All subjects had 
to be able to cope with the investigation according to the study procedure. The 
methods of TMS and intramuscular electrodes were not causing pain, but they 
could be experienced to some extent inconvenient. 

51
5. RESULTS
5.1. CFPP and schizophrenia (study I)
There were no signi cant differences between subjects with schizophrenia and 
controls in the CPFVs (Table 3), but subjects with schizophrenia seemed to stand 
more stable both during eyes open and eyes closed, compared to the controls. The 
difference between the groups was signi cant (median change, p = 0.0006). The 
visual control did not seem to have a signi cant role in maintaining the postural 
balance in upright position. The change of the CPFV was much lower in subjects 
with schizophrenia than in controls, which seemed to have it more dif cult to hold 
their upright standing position stabile eyes closed. Also the mean CPFV was lower 
among the subjects with schizophrenia during eyes closed condition. 
Subjects with schizophrenia tended to lean to the left and the controls to the 
right side. The difference between the groups respective the lateral body shift 
was suggestively signi cant (p = 0.025). The body shift and its range in anterior-
posterior direction seemed to be wider among the subjects with schizophrenia, but 
the difference between the groups was not signi cantly different (p=0.05). Figure 3 
presents position shifts (posturographies) of a standing  subject with schizophrenia 
and a control person during eyes open and eyes closed conditions and in anterior-
posterior and lateral directions. 
Table 3. presents the obtained CPFV measures (means+SD and medians) during eyes open and 
eyes closed conditions, the change of CPFV from eyes open to eyes closed condition; lateral 
and anterior-posterior (AP) shifts of body position among schizophrenics (n = 22) and their 
normal controls (n = 14) in study I. In shifts during eye closure, negative values denote moving 
to the left (lateral) and backwards, positive values denote shifts to the right and forwards. 
NS= non-signiﬁ cant, CL= conﬁ dence limit, CPFV= Center Point of Force Velocity.
 Table 3. CPFV eyes 
open NS 
(cm/s)
CPFV eyes 
closed 
NS(cm/s)
Change of CPFV from 
eyes open to eyes 
closed condition, % 
Lateral shift 
during eye 
closure (cm) 
AP shift during eye 
closure NS(cm)
Controls mean+SD 0.91+0.22 1.54+0.46 68+22 0.45+1.20 1.10+1.17
median 0.84 1.35 70* 0.52** 0.99
range 0.68-1.46 0.95-2.44 29-119 -2.50-2.84 -0.40-3.71
95% CL of 
median 0.73-1.12 1.26-2.21 44-88 -0.09-1.19 -0.04-1.89
Schizo-
phrenics mean+SD 1.07+0.34 1.43+0.35 38+25 -0.44+1.31 0.37+1.82
median 0.98 1.37 36* -0.28** 0.42
range 0.53-1.80 0.81-2.34 -10-91 -4.34-1.74 -3.41-5.74
95% CL of 
median 0.84-1.23 1.22-1.68 30-54 -0.93-0.57 -0.67-1.35
*p < 0.05, median difference 30, 95% CL:s of median difference are 12 and 42 
**p < 0.05, median difference 0.85, 95% CL:s of median difference are 0.19 and 1.51. 
(Mann-Whitney two-tailed test for differences between the groups)
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5.2. TMS AND RLS (study II)
The groups (i.e. RLS and controls) did not differ signi cantly from each other in 
respect of MEPs and their peripheral components (F-waves, MDLs) (tables 4a and 
4b). Thus, the corticospinal motor pathways functioned correctly in RLS compared 
to controls. No signi cant side-to-side differences were observed within the groups 
(i.e. RLS and controls). 
Table 4a and 4b  present results (mean + SD) of study II of motor conduction times (MCT), central motor 
conduction times (CMCT), F-waves and motor distal latencies (MDL) in milliseconds (ms) after transcranial 
magnetic stimulation (TMS) on the dominant and non-dominant motor cortex of brain. Responses were 
measured in the target muscles of Abductor Digiti Minimi (ADM) (table 4a) and Tibialis Anterior (TA) (table 
4b) in respective dominant and non-dominant extremities. The measured values did not differ signiﬁ cantly 
between the subjects with RLS and controls
Table 4a
Variable ADM Non-dominant ADM Dominant
 (ms) Control RLS Control RLS
MCT 21.11.1 21.41.0 21.21.3 20.80.7
CMCT 6.21.1 7.50.6 8.51.7 6.80.4
F- wave 24.72.9 23.5.8 24.14.1 23.41.3
MDL 2.50.2 2.20.3 2.70.4 2.20.3
Table 4b
Variable TA Non-dominant TA Dominant
 (ms) Control RLS Control RLS
MCT 28.61.6 28.23.0 29.22.3 28.12.5
CMCT 11.01.2 11.33.2 11.91.6 11.72.9
F- wave 26.72.1 24.11.8 26.21.5 23.71.7
MDL 4.30.6 4.90.4 4.20.6 4.60.6
The central inhibition showed tendency to disrupt and consisted of up to one to 
three, separate compounds of CSPs (Table 5). The number of the CSPs (meanSD) 
was signi cantly higher in both ADMs (dominant: 1.51.1 and non-dominant: 
1.70.8; p<0.05) and in the dominant TA (RLS:1.31;controls:1.20.4; p<0.05) 
in subjects with RLS compared to the controls, but no significant differences for 
the number of the CSPs were obtained in the non-dominant TA (RLS: 
1.50.6; controls: 1.30.5; p>0.05).
The separate compounds of the CSPs (Table 5) did not differ signi cantly on the 
duration or on the latency between the RLS and the control groups. The recurrent 
CSPs showed a diminishing duration. Table 5 presents the results of measurements 
in central silent periods (CSP) in study II.
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5. RESULTS
5.3. TMS and schizophrenia (study III)
The groups (i.e. schizophrenia and controls) did not differ signi cantly from each 
other in respect of MEPs or their peripheral components (F-waves, MDL). Within 
the groups there could not be demonstrated any signi cant side-to-side differences. 
The function of descending corticospinal motor pathways in schizophrenia seemed 
to be intact compared to healthy controls. Table 6 presents the main results of TMS 
measurements.
The central inhibition was disrupted into several separate compounds, silent 
periods (CSP) predominantly in subjects with schizophrenia. After each TMS 
impulse there could be up to one to three sets of inhibited muscular activity within 
500 ms after the stimulation. The number of CSPs (mean+SD) differed statistically 
signi cantly in the dominant ADM in subjects with schizophrenia from controls 
(1.8+0.6, U=13.5, p=0.004, signi cant even after Bonferroni correction, p=0.024) 
but more than one sets of CSPs could also be observed in the non-dominant 
ADM and in the dominant TA in subjects with schizophrenia, even though these 
differences were not statistically signi cant. Table 6 presents the results of the 
TMS measurements and signi cant differences in the subjects with schizophrenia 
compared to controls.
High PANSS scores correlated signi cantly with multiple CSPs in the non-
dominant ADM (Table 2). The users of conventional antipsychotics seemed, even 
though this was not statistically signi cant, to show shorter CSPs and in average 
more extrapyramidal signs, like akathisia and abnormal involuntary movements. 
The PANSS and SAS rates did not differ signi cantly between the users of atypical 
or conventional antipsychotics (Table 2). The users of atypical antipsychotics seemed 
to have longer CSPs and disrupted central inhibition, mainly in the non-dominant 
body side and in the under extremities. They also tended to have the longest CSP 
durations (Table 6).
5.4. CFPP and RLS (study IV)
Table 7 presents the mean values of CPFV in participants with RLS and in controls 
eyes open and eyes closed and the change in CPFV and in average position shifts 
(cm) in anterior – posterior and lateral directions from eyes open to eyes closed 
conditions. The main  nding of the study was that with eyes open the sway velocity 
(mean+SD) in non-treated condition of subjects with RLS (CPFV eyes open: 
0.68+0.12) was signi cantly (p<0.05) lower than in the controls (CPFV eyes open: 
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5. RESULTS
0.99+0.34), whereas CPFV eyes closed did not differ signi cantly (p>0.05) between 
RLS group (1.62+0.47) and controls (1.68+1.11). The Romberg´s quotient (mean + 
SD) was also signi cantly higher in subjects with RLS (2.42+0.71; p<0.05) than in 
controls (1.69+0.45).  With eyes closed the sway velocity in subjects with RLS did 
not differ signi cantly from the level of sway velocity of the controls. 
Table 7.  presents the mean values+SD of CPFV (Center Pressure Force Velocity, cm/s) in participants with 
RLS (RLS) and in controls eyes open and eyes closed and the change in CPFV and  in average position shifts 
(cm) in anterior – posterior (+A / - P) and lateral (+ rightwards/ - leftwards ) directions from eyes open to 
eyes closed conditions. Legend: SD = standard deviation, RQ= Romberg´s quotient, N=number of subjects
Table 7.
CPFV cm/s 
EYES OPEN
CPFV cm/s 
EYES CLOSED RQ
CPFV cm 
change
A-P cm 
average 
change
LAT  cm 
average 
change
VARIABLE
GROUP
RLS non- 
medic. N=12 0.68*+0.12 1.62**+0.47 2.42*+0.70 0.94+0.44 1.81+1.86 -0.85+0.72
RLS medic.  
N=12 0.73+0.15 1.61***+0.54 2.21+0.67 0.88+0.47 1.48+1.67 - 1.96+1.02
       
CTRL N=12 0.99*+0.34 1.68****+1.11 1.69*+0.45 0.69+0.82 0.24+0.20 -1.67+0.69
Signiﬁ cant differences (p < 0.05) were obtained in the following measures:
1.*CPFV eyes open was signiﬁ cantly slower in non-treated RLS subjects than in controls 
2.*RQ was higher in non-treated RLS subjects than in controls 
3. CPFV eyes closed compared to eyes open was signiﬁ cantly higher within **non-treated, *** treated 
and ****control group, reﬂ ecting normative change between visual and non-visual conditions 
After intervention with pramipexole the difference in CPFV (mean+SD) condition 
eyes open between RLS (0.73+0.15) and control (eyes open: 0.99+0.34; p=0.052) 
disappeared, while the sway velocity of RLS group seemed to approach the level of 
the controls eyes open and eyes closed (1.68+1.11; p=0.67). Pramipexole relieved 
subjective and objective symptoms in subjects with RLS, seen as decrease of the 
mean values of VAS (67.27 – 20.45) and mean scores of BAS (1 – 0.33). Table 8 
presents obtained scores for severity of symptoms and the changes measured in 
Visual analogue scale (VAS) and BAS (Barnes Akathisia Scale) in subjects with 
RLS (Table 8). 
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Table 8.  
Subjective symptom severity (mean value + SD) gathered in a visual analogue scale (VAS, scale 0–100%) 
and assessed symptoms of akathisia (Barnes akathisia rating scale, global scores) in subjects with RLS 
in study IV. 
Legend: VAS max= Maximum symptom severity during the past two weeks; non-medicated
  VAS 1= Symptom severity during the past 24 hours non-medicated
  VAS 2= Symptom severity during the past 24hours after intake of medication 
  BAS 1= Scores of akathisia non-medicated
  BAS 2= Scores of akathisia after intake of medication
Evaluated 
symptoms 
in RLS n
Mean
values/
change %+SD
VAS max 11 56.82+16.77
67.27+19.25
20.45+19.24
1.00+1.04
0.33+0.64
decrease
~ 60%
VAS 1 11
VAS 2 11
BAS 1 12
BAS 2
VAS1-VAS2 and
BAS1-BAS2
12
Subjects with RLS tended to sway in average more forward, while eyes closed 
all study participants tended to sway in average more leftwards. Table 9 presents 
the mean values and standard deviations of the CPF shift in anterior – posterior 
and lateral directions in conditions eyes open and eyes closed in non-medicated 
and medicated subjects with RLS and in controls.
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Table 9. 
Mean values and standard deviations  (M+ SD) of the CPF shift (cm) in anterior - posterior and lateral 
directions in conditions eyes open and eyes closed in non-medicated (RLS 1) and medicated (RLS 2) 
subjects with RLS and in controls (CTR) in study IV. 
Legend: AP= (+anterior, - posterior direction), Lat= lateral direction (+ rightwards, - leftwards), max= 
maximum, ave=average, n=number of subjects, SD =standard deviation
VARIABLE
GROUP
APmax
eyes 
open
APmax
eyes
closed
AP ave
eyes
open
AP ave
eyes
closed
Lat max
eyes 
open
Lat max
eyes 
closed
Lat ave
eyes
open
Lat ave
eyes
closed
RLS 1       M
n=12
              + SD
0.23 0.37 -1.16 0.661 -0.11 0.44 1.79 -0.062
0.57 1.10 1.42 0.77 0.54 0.97 0.55 0.36
RLS 2      M
n=12
              + SD
0.26 0.38 -1.01 0.473 -0.40 0.01 1.93 -0.034
0.60 1.07 1.16 0.81 0.49 1.03 0.83 0.45
CTR
n=12        M
             
              + SD
0.01 -0.22 -0.07
  
 0.17 -0.35 -0.15 1.58 -0.095
0.88 1.33 1.65    0.65 0.70 0.87 0.51 0.38
Signiﬁ cant differences (p<0.05, Wilcoxon) between conditions eyes open and eyes closed were 
obtained:
1)within non-treated RLS group in AP average (*Z=-2.51) and lateral average (**Z=-3.06) 
position shift
2)within treated RLS group in AP average(***Z=-2.59) and lateral average(****Z=-3.56) position 
shifts
3)within controls in lateral average (*****Z=-3.06) position shift 
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6. DISCUSSION
6.1. General aspects (I–IV)
Schizophrenia and Restless Legs Syndrome (RLS) are disorders with multifactorial 
pathogenesis. Schizophrenia is considered to be a neuropsychiatric disorder, 
associated with impairment of cognitive and perceptive functions, frequently 
resulting in disorganized thinking, lateralized motor symptoms and attentional 
abnormalities. RLS is considered to be a sleep disorder, associated with sensorimotor 
symptoms without impairment of cognitive functions. Symptoms of RLS may come 
to manifestation due to several factors such as circadian (diurnal) rhythm, due to 
lack of muscular activity in the lower extremities and the set of the body position. 
Although the cardinal symptoms of schizophrenia are considered to be mental, 
both schizophrenia and RLS are associated with motor symptoms. The origin of 
these motor symptoms and at the same time the pathomechanisms behind these 
disorders are assumed to involve dopamine regulating systems in the CNS. This 
point of view is con rmed by the facts, that antidopaminergic antipsychotics are 
effective in treating psychotic symptoms of schizophrenia, whereas dopaminergic 
agents are useful in relieving symptoms related to movement disturbances in 
RLS. Conventional antipsychotics often induce extrapyramidal side effects, such 
as dyskinesias, tremor, rigidity and akathisia, which can easily be misinterpreted 
symptoms of some other clinical, somatic or neurologic disorders or exhibit 
symptoms of the actual mental illness. Especially neuroleptic induced akathisia 
in schizophrenia resembles symptoms related to RLS, such as subjective inner 
restlessness and objective restless movements of legs, sometimes appearing in the 
upper extremities, too. 
CNS motor control, especially the generators that re ect the function of the basal 
ganglia, was in the focus of this study because of the dyskinetic features of these 
disorders. The central motor system is a very complex system, that is provided with 
a certain hierarchy of control levels, to be able to maintain the most important and 
vital functions for the human body. The forebrain represents the highest evolutionary 
level and the spinal cord the lowest level in the CNS. Then highest levels, like the 
association areas of neocortex and the basal ganglia have a strategy function, the 
middle levels, like the motor cortex and cerebellum have a tactic function and the 
lowest level, the brain stem and the spinal cord have executive functions. A direct 
motor loop through the basal ganglia of the brain evidently facilitates the initiation 
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of voluntary movements. Thus, if the inhibition of thalamus were increased by the 
basal ganglia, this would result in hypokinesia, reduction of movements, whereas the 
decreased basal ganglia output would result in increased movements, hyperkinesia 
(Bear, 2007). 
The postural control is coordinated by the vestibular system, proprioceptive 
system and vision. Circadian rhythm, some neurological illnesses and sensorimotor 
disturbances as well as tiredness, loss of sleep or other one`s attentional ability 
disturbing factors may individually in uence the postural control. In turn, 
sportsmen, for example shooters, may have better postural balance coordination. 
There could not be found earlier studies focusing on the postural control in RLS. 
Postural control has not been a much investigated topic in schizophrenia, either. 
At the time of our TMS study procedures took place, TMS had been introduced as 
a promising investigation method. 
The aim of this study was to demonstrate with the help of modern investigation 
methods and appropriate technical applications that movement disturbances in 
schizophrenia and RLS do not only clinically resemble each other but also originate 
in the same generator area in the central nervous system (CNS). 
6.2. Material and methodological questions
6.2.1. SPECIAL QUESTIONS CONCERNING SUBJECTS (STUDIES I–IV)
Handedness is a complex representation of distinguished lateralized functions 
of CNS. In our studies, handedness was assessed with the help of Edinburgh 
Handedness Inventory, but footedness was mainly estimated by asking the subject´s 
own adjustment. Handedness and footedness are not always equal, which makes 
the interpretation of the results complicated. In our study the dominant brain part 
was determined due to evaluated handedness for each subject. Because of this 
possibly interfering factor, much attention was not paid to asymmetric  ndings in 
the study. No distinct conclusions could be drawn concerning the question of the 
CNS lateralization in schizophrenia. 
The controls were in general healthy persons and they reported physical well-
being. The results of the controls were consistent within the group and in comparison 
to normal values of earlier studies. The controls in both TMS studies were selected 
from the same control group, aiming to match the gender and age as appropriate. 
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6.2.2. TRANSCRANIAL MAGNETIC STIMULATION (STUDIES II–III)
A lot of research has been focused on the motor control in schizophrenia and in 
RLS with the help of transcranial magnetic stimulation (TMS) that is a useful tool 
with its different applications to investigate the function of the motor pathways 
and the central inhibition in the central nervous system. Earlier results tend to vary 
depending on the applied material and methods (Haraldsson et al., 2004). Therefore 
we chose a different, accurate technique for recording the responses in the muscles. 
Instead of commonly used surface electrodes, we inserted an intramuscular pair 
of monopolar electrodes in the target muscles. This recording method provides 
a possibility to record a high number of single motor units simultaneously, thus, 
re ecting a comprehensive part of the function of the motor track to the target muscle 
(Nandedkar et al., 1994, Barkhaus et al., 1994, 2006). The changes in muscular 
electrical activity, including the  ring frequency, the high frequency components 
of the muscular activity could be evaluated (Rosenfalck, 1969)
The recording with intramuscular electrodes made it possible to distinguish the 
high frequency components of the muscle activity (Rosenfalck, 1969) and thus to 
determine the onset and end of the silent period precisely and to detect all recurrent 
compounds of CSPs. The methodological differences could explain the variable 
results for example in the latency of MEP in schizophrenia (Puri et al., 1996) and in 
the duration of silent period (Davey et al., 1997, Fitzgerald et al., 2002a,b, Daskalakis 
et al., 2002). Results elicited in homogeneous and heterogeneous subject groups 
with the help of different types of TMS techniques makes the comparison of these 
results complicated (Wobrock et al., 2008, 2009).
The study sample sizes were initially planned to be small, especially in concern of 
the TMS studies. The recording technique and procedure required high professional 
investigatory skills in neurophysiology and appropriate technical applications. 
During the measurements, the subjects needed to possess adequate skills to cope 
with the investigator and follow the required study protocol. 
In these studies our main interest was to investigate central inhibition and to 
characterize the function of the descending corticospinal motor pathways down to 
the target muscles. Single pulse TMS was chosen because of applicable and suitable 
method for this purpose. The stimulation intensity constantly exceeded the motor 
threshold level and could be easily con rmed as a motor response.  The round coil 
was chosen because of its wider stimulation area compared to butter y coil type. 
Thus, it became easier to  nd the appropriate cortical site for stimulation of the 
target muscles.
Inhibitory responses were measured during maximal activation of target 
muscles. During maximal contraction the electrophysiological muscle interference 
pattern re ects the comprehensive motor recruitment and can be veri ed by 
intramuscular needle electrode measurement. The temporary complete suppression 
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of interference pattern mirrors the inhibition of motor activation during maximal 
muscle contraction.
Based on literature (Hess et al., 1987, Rothwell et al., 1987) the MEPs show 
amplitude variation to the considerable extent. We did not  nd relevant to assess 
amplitude sizes in this study. Generally recommended implications for measuring 
MEPs and CSP after TMS of motor cortex were applied (Säisänen et al., 2008).
6.2.3. COMPUTERIZED FORCE PLATFORM POSTUROGRAPHY (CFPP)
The CFPP is considered to be a nonspeci c, but a reliable method that allows the 
investigation of sensorimotor neural and attentional mechanisms in a standing 
subject (Kingma et al., 2011). The study procedures can easily be repeated in large 
populations (Forsman et al., 2007), but because of the pilot art of the studies, the 
study samples were limited. Center point of pressure forces (CPPF) and the center 
point of force velocity (CPFV) are the most commonly used parameters that are 
easily measured and re ect the changes of the imaginary center point forces of the 
body mass and its path velocity sway velocity, during one´s stance with eyes open 
and eyes closed conditions on the platform.
The room used for the measurements was tried to keep unchanged and peaceful. 
The speci c features of the  subject`s disorder, for example the regular and optimal 
timing for the measurements (RLS, controls) and the mental and motor conditions 
(schizophrenia) were taken into account to be able to follow the study protocol 
accurately. Regarding RLS, the upright standing position requires active muscular 
work and stimulates CNS feedback, thus, the upright stance may not be the most 
optimal position to reach the most severe symptoms of RLS in whole. However, 
it can be concluded that the sensitivity of the CFPP method was high enough to 
differentiate signi cant distinct differences in both disorder groups. These pilot 
art studies were the  rst ones to our knowledge to explore the maintenance of the 
postural balance in these chronic disorders.  
6.3. Results of TMS studies II and III
The results of our TMS studies con rmed some results of earlier studies, showing 
that the function of descending motor pathways is correct in schizophrenia and 
RLS. We did not detect any signi cant side-to-side differences concerning the TMS 
results within any of the study groups. Earlier studies have reported, that in healthy 
persons CSPs are less excitable in the dominant motor cortex (Priori et al. 1999) 
and that healthy right-handers show more inhibition and less facilitation than left-
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handers (Civardi et al. 2000). These  ndings may support the signi cance of the 
asymmetric CSP results observed in both disorders compared to healthy controls in 
this study, but because of the interfering factors, such as possible medication effects 
and inclusion of right-and left-handed subjects with schizophrenia in these studies, 
the  ndings referring to deviant asymmetry have to be interpreted with concern. 
Interestingly after TMS we discovered multiple central silent periods (CSP) in 
the respective target muscle in schizophrenia and RLS both instead of one complete 
period of maximal suppression in the voluntary activated muscle. The number of 
these separate CSP compounds was signi cantly higher in the dominant Abductor 
Digiti Minimi muscle (ADM) in RLS and in schizophrenia compared to controls. 
In literature, the early part of the CSP is described to re ect a suppression of the 
spinal motor nuclear activity mediated directly from the motor cortex, whereas the 
later part of the CSP re ects a suppression of the muscle activity by supraspinal 
structures presynaptic to fast descending motor pathways (Cantello et al., 1992). 
It is unclear if the  rst compounds of CSPs in our study could be interpreted equal 
to the cited early spinal parts and the later compounds with supraspinal parts.   
6.3.1. SPECIAL CONSIDERATIONS IN REGARD WITH STUDY III AND DOPAMINE 
INTERACTIONS
In our study atypical antipsychotics tended to lengthen CSP preferably in the non-
dominant side but to promote occurrence of multiple CSPs on the dominant body 
side. This lengthening effect could be based on the GABA(B)ergic regulation of 
the inhibitory neuronal circuits by atypical antipsychotics and on the decrease of 
dopamine regulation in the CNS.
Atypical antipsychotics improve psychiatric symptoms including anxiety but 
induce less clinical and distressing extrapyramidal symptoms, especially rigidity. 
Conventional antipsychotics improve mental conditions with psychotic features, by 
decreasing dopamine release in the CNS, which often results in subjective inner 
distress, clinically observable restlessness, stiffness and rigidity in one´s body and 
limbs (Stahl, 2010) forcing one to move oneself, resembling symptoms in RLS. 
In our TMS study atypical antipsychotics seemed to normalize or even enhance 
the central inhibition in schizophrenia.  The shortened CSPs could be based on 
the pathomechanism of the illness itself or on the long-term use of conventional 
antipsychotics. 
In both schizophrenia and RLS the upper extremities were chie y affected by 
multiple CSPs and the dominant hemispheric side with respective stimulation 
sites. The  ndings were signi cant, especially on the dominant ADM. This could 
be explained by the fact, that in schizophrenia extrapyramidal symptoms preferably 
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appear in the upper dominant extremity. However, a clinically known fact is that EP-
symptoms such as rigidity induced by antidopaminergic agents are easily identi able 
in the non-dominant upper extremity. The phenomenon is evidently linked to 
hypodopaminergia unrelated to treatment with antipsychotic agents (Caliguri et 
al. 1993), but could be further strengthened by antidopaminergic agents. 
Due to multiple CSPs in RLS and in schizophrenia both, this alteration in 
central inhibition could be assigned to hypodopaminergia. Central dysregulation of 
dopamine transmission may promote psychiatric symptoms, but also play a crucial 
role in causing motor changes (Jarcho et al., 2012). Both disorders, particularly 
concerning the motor symptoms, according to literature are supposed to have their 
pathophysiological origin in the basal ganglia or close to the subcortical locations 
that coordinate voluntary movements in the CNS.
The complex interaction mechanisms between the CNS neurotransmitters 
along the neural motor pathways may be impaired in RLS and schizophrenia. 
Thus, multiple CSPs could re ect an imbalance in the neurotransmitter (GABA, 
DA) regulating systems in the extrapyramidal tracts (Stahl, 2010). In this study, 
slightly reduced central inhibition in users of conventional antipsychotics could 
be connected to slightly increased level of extrapyramidal symptoms (BAS, AIMS, 
p=0.05) re ecting tendency to hyperkinesias, whereas the enhanced inhibition in 
the users of atypical antipsychotics could re ect tendency to hypokinesias. Some 
properties of CSPs, like the duration, may be connected to positive or negative 
symptoms of schizophrenia (Wobrock et al. 2009, Liu et al., 2009). In this study a 
positive correlation between multiple CSPs in the non-dominant ADM and higher 
PANSS scores in schizophrenia was obtained. Severe symptoms of schizophrenia 
often need treatment with high doses of antipsychotics, which may again refer to 
hypodopaminergia.  However, the relevance of this  nding is unclear.
Earlier studies have shown inconsistent results on the duration of the CSPs in 
RLS. Modi ed CSP con gurations were observed in RLS and in Parkinson’s disease. 
A disturbed basal ganglia control and output to the primary motor cortex have been 
suggested to explain these  ndings (Ondo et al., 2002, Priori et al., 1994, Cantello et 
al., 2007, Nardone et al., 2006). The TMS measurements of this study in RLS were 
not performed during the most optimal time considering the typical occurrence of 
RLS symptoms- in between the morning to day-time- a possible reason, why subjects 
with RLS did not show alteration in duration of CSPs compared to control group.
The signi cant occurrence of recurrent inhibitions among ADMs in our RLS 
subjects could be contributed to the fact that arms are generally impacted in the 
chronic forms of RLS. Since central inhibitory circuits of the hand and foot motor 
cortex areas are connected to each other in human (Tergau et al., 1999), this might 
partly explain the occurrence of multiple CSPs uncovered in our study in the upper 
and lower extremities in RLS and schizophrenia. On the other hand, a reduced 
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central inhibition has been found to correlate with sensory-motor symptoms in RLS, 
especially involving arms (Quatrale et al., 2003). All RLS subjects and their matching 
controls were right-handed, thus, this should not be an interfering factor in this 
study. However, the research method used in this study to assess the hemispheric 
dominance was probably not comprehensive enough. 
Since manifestations of mental symptoms in RLS are not typical compared to 
disorders such as schizophrenia, the phenomenon of multiple CSPs might not re ect 
the disorganization of mental conditions. Because the inhibitory motor control were 
more prone to disrupt in the important dominant hemispheric side, this could also 
be understood as a protecting mechanism of the higher levels of the motor control 
hierarchy to preserve the inhibitory functions operational. This could be regarded as 
a compensation mechanism “ ghting” against hypodopaminergia and the inhibitory 
de cit by producing recurrent inhibition. 
6.4. Results of the CFPP studies
The posturographic studies demonstrated, that among subjects with schizophrenia 
closing the eyes had less impact on the center point of velocity (CPFV, cm/s) than in 
controls. The average change of the sway direction during eye closure tended to shift 
to the right in controls but to the left in subjects with schizophrenia. Interestingly, 
subjects with RLS held signi cantly more stable posture during eyes open, but 
their CPFV approached the CPFV level observed in controls when the eyes were 
shut. The average shift of the CPF in subjects with RLS and controls directed to the 
left and forward during the eye closure. The differences in the anterior-posterior 
shift between the two positions within the RLS group and the lateral shift were 
signi cant within both groups. 
The average CPF shift during eye closure tended to direct to the left in RLS 
and schizophrenia. In schizophrenia this could mean that eye closure facilitates 
the subclinical right hemineglect (Early et al. 1989, Harvey et al., 1993), however, 
the effects of medication cannot be ruled out (Lauerma et al. 1994). The symptom 
relieving dopaminergic agent seemed to have a normalizing effect on the postural 
sway velocity and on the symptom severity in RLS. This was seen as reduction of 
akathisia (BAS) and subjective symptom severity (VAS). However, pramipexole did 
not seem to affect the sway area in RLS. Even though the tendency to sway leftwards 
during eye closure was present in both disorders, the sway was not corrected after 
pramipexole intervention in RLS. Thus, this phenomenon may not purely be linked 
to hypodopaminergia. 
Other motor control and sensory-motor integrative functions coordinating 
systems of the CNS, like cerebellum and related circuits are supposed to be involved 
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in the deviant maintenance of  the postural stability in schizophrenia, too (Kent et 
al., 2012). The control groups exhibited different results with respect to the average 
CPF shift in these CFPP studies, thus, the CPF shift alterations in general need 
further investigation of these disorders in comparison to controls among larger 
sample groups. 
The study results propose that visual component has lost its dominance in the 
balance control in subjects with schizophrenia while in subjects with RLS, vision 
aided to hyperstabilize the upright stance. Therefore the strategy of maintaining 
postural balance and utilize visual information may be impaired in different ways 
in schizophrenia and RLS. Circadian rhythm regulating organs are located in the 
thalamus. In both disorders the thalamus, as a subcortical generator of motor control 
and postural control, may be the key location in the CNS. An altered feedback 
system of the CNS is suggested lay behind the movement disturbances related to 
RLS, at least.
6.5. Limitations of the study (I–1V)
6.5.1. STUDY I
Effects of medication cannot be ruled out when interpreting the results because other 
than dopamine-related neural pathways may also be involved in the management 
of postural re exes. Thus, it is possible that altered postural control in subjects 
with schizophrenia observed in this study is also linked to other de cits, such as 
movement and cognitive disturbances, subclinical right hemineglect and long-
term medication effects. The small number of subjects with schizophrenia made it 
impossible to explore plausible differences between paranoid (n=8), disorganized 
(n=2) and undifferentiated (n=12) subtypes of schizophrenia. 
6.5.2. STUDY II
The number of subjects with RLS was limited due to the recruitment procedure. 
The TMS investigations were performed on two separate dates in the city of Turku. 
Some volunteers were unable to participate the investigation procedure on scheduled 
days, which reduced the number of available subject number. The subjects with 
RLS in the TMS study were recruited from a well selected and clinically examined 
study population from the city of Turku community and university clinics. An 
experienced sleep-researcher interviewed the subjects with RLS and ruled out 
PLMD. At the time this study procedure and the subject recruitment took place, 
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polysomnographic investigations were not common or available. The age difference 
between the controls and the RLS subjects was expected to be signi cant, because 
the controls were recruited from working age population while the typical RLS 
patient was elderly and/or retired from the workforce.
6.5.3. STUDY III
The age difference was not signi cant between the schizophrenia and control groups. 
The recruited participants in the study did not differ considerably regarding the 
motor symptoms or EP symptoms. Other limitations in the TMS study were the 
mixed use of various antipsychotics and lorazepam by some of the subjects. In 
addition, some participants with schizophrenia were left-handed. The limited 
number of subjects with schizophrenia in the study did not permit exploration 
of differences between paranoid and undifferentiated subtypes of schizophrenia.
6.5.4. STUDY IV
Limitations of this study was the small number of subjects, a higher number of 
female (n=11/ total 12) participants with RLS and a lack of placebo control/ versus 
non-medicated subjects. In addition, the measurements were carried out during 
a non-optimal position (standing condition) or timing (late afternoon) to capture 
the maximum symptom severity. The age difference was expected to be signi cant 
based on the similar reasons as in the second study. Because all subjects wore 
their footwear while standing on the platform, the property of the contact surface 
underneath the feet between the shoes and the platform surface could have slightly 
in uenced the results (Qiu et al., 2012).
6.6. Summary: the aims and the results of the study (I–IV)
6.6.1. STUDY I
Subjects with schizophrenia did not  nd more dif cult to maintain the postural 
balance than healthy controls. However, the visual impact on the postural sway 
was less signi cant for subjects with schizophrenia than for controls. The subjects 
with schizophrenia in this study were not suffering from severe extrapyramidal 
symptoms (i.e. symptoms of Parkinsonism). Therefore it is possible to assume the 
de ciencies in handling visual control and sensorimotor stimuli may modulate 
postural control in schizophrenia.
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6.6.2. STUDIES II AND III
As expected subjects with schizophrenia and subjects with Restless Legs Syndrome 
with similar types of clinical manifestations of motor symptoms seemed to show 
similar inhibitory responses such as disrupted central silent periods in the upper 
extremities. This might refer to hypodopaminergia and the connection to central 
dopamine dysregulation may be one of the movement symptoms releasing 
background factors.  As was expected, corticospinal motor pathways in the subjects 
of these studies were found to function normally.
6.6.3. STUDY IV
The intervention with a dopaminergic agent (pramipexole) relieved RLS symptoms; 
however a placebo-effect cannot be excluded. Pramipexole caused a little growth of 
the sway velocity and the sway area. Interestingly the visual in ux seemed to have a 
greater impact on the RLS subjects’ ability to control their upright stance compared 
to controls. Eyes shut and after intake of a dopaminergic agent, the difference 
disappeared. The study results were consistent with the earlier investigations on the 
effects of dopaminergic agents on the postural control in persons with Parkinson´s 
disease. However, the role of vision in the postural control and suggested altered 
sensorimotor feedback in the CNS need to be researched further.
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7. CONCLUSIONS
1. TMS studies con rmed that the elementary function of the 
central motor pathways was intact in schizophrenia and in RLS. 
No signi cant hemispheric differences were observed within the 
groups (i.e. schizophrenia, RLS, controls).
2. Central inhibition after TMS was observed to be changed in 
schizophrenia and RLS in the same way: it was disrupted into 
multiple central silent periods (CSPs). These disrupted CSPs 
were preferably located in the dominant hemispheric side and 
especially the motor cortex area of hand muscles. 
3. The CFPP studies demonstrated different patterns of utilizing 
vision in maintaining the upright posture in schizophrenia 
and RLS: the results suggest a defect of visual compensation 
in schizophrenia on the postural control whereas a 
hypercompensatory effect of visual information on the postural 
control was observed in RLS. 
4. Hypodopaminergia is considered to be one of the etiological 
factors involved in the pathomechanism of the movement 
disturbances. An imbalance of different CNS neurotransmitters 
and an impaired regulation of their interactions in the subcortical 
brain parts, such as basal ganglia is suggested to lie behind the 
observed motor control changes. 
5. A deviant lateralization of the CNS functions in schizophrenia or 
in RLS could not be veri ed in this study by using TMS or CFPP: 
despite the consistency that was obtained in the results pointing 
to the hemispheric asymmetry in concern of the CSPs and the 
average sway direction during eye closure in schizophrenia and 
RLS, the  ndings are not signi cant because of the previously 
mentioned limitations of the studies. 
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8. FUTURE CONSIDERATIONS
These studies aimed to solve questions which have not been the focus of earlier 
research concerning schizophrenia and RLS. Motor control was investigated with 
the use of methods (TMS and CFPP) considered to be reliable and relevant, although 
not implemented in wide clinical practice. The CFPP methods and measurements 
applied in studies I and IV can be performed in large population. The TMS technique 
utilized in studies II and III was more complicated and requires the knowledge of 
competency in clinical neurophysiology. In general, these methods and procedures 
are considered to be useful in further investigations.
CFPP can be applied in clinical practice when evaluating symptoms associated 
with postural control dif culties. TMS can be applied in clinical practice to check 
effects or side effects induced by neuroleptic/ dopaminergic agents or to explore 
origins of movement disturbances, especially in severe stages of illness. 
However, the study procedures should be replicated in larger study populations, 
in placebo control, and in comparison of non-treated subjects with treated 
subjects and with other dopamine-related chronic illnesses such as Parkinson´s 
disease. By combining several different investigation methods such as TMS with 
appropriate brain imagination techniques, neuropsychological investigations, gait 
analysis, polysomnography and CFPP with integrated further sensorimotor testing 
applications, it would be possible to achieve a more comprehensive view of the 
over-lapping and differing symptom  elds in these diagnosis groups. 
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